Abstract
Excessive lipid accumulation is a serious condition. Therefore, we aimed at developing safe strategies using natural hypolipidemic products. Lingzhi is an edible fungus and potential lipid suppression stimulant. To use Lingzhi as a functional hyperlipidemic ingredient, response surface methodology (RSM) was conducted to optimize the time (X1) and enzyme usage (X2) for the hydrolysate preparation with the highest degree of hydrolysis (DH) and % yield. We encapsulated the hydrolysates using nanoscale liposomes and used proteomics to study how these nano-liposomal hydrolysates could affect lipid accumulation in adipocyte cells. RSM analysis revealed X1 at 8.63 h and X2 at 0.93% provided the highest values of DH and % yields were 33.99% and 5.70%. The hydrolysates were loaded into liposome particles that were monodispersed. The loaded nano-liposomal particles did not significantly affect cell survival rates. The triglyceride (TG) breakdown in adipocytes showed a higher TG increase compared to the control. Lipid staining level upon the liposome treatment was lower than that of the control. Proteomics revealed 3425 proteins affected by the liposome treatment, the main proteins being TSSK5, SMU1, GRM7, and KLC4, associated with various biological functions besides lipolysis. The nano-liposomal Linzghi hydrolysate might serve as novel functional ingredients in the treatment and prevention of obesity
Keywords: RSM, Lingzhi, hypolipidemic activity, peptides, 3T3-L1
1. Introduction
Modern functional food products are available on the market, ranging from isolated nutrients, dietary supplements, and specific products to processed or engineered foods. Peptides from foodstuff are candidates for functional food ingredients due to their beneficial health aspects such as immune-boosting, anti-oxidative stress, hypolipidemic and tumor suppressing activity [1,2]. One of the above-mentioned beneficial aspects is the hypolipidemic activity on adipocytes, affecting lipid storage, directly associated with obesity, a contemporary health problem. Obesity is caused by excessive triacylglycerol (TAG) accumulation in the adipocytes. Increasing TAG breakdown or hypolipidemic activity might contribute to reducing body fat and triglyceride (TG) levels. Several natural-sourced peptides could be combined with foodstuffs, and their effective delivery could display beneficial aspects [3].
Most edible mushrooms such as Volvariella volvacea, Lentinula edodes, and Ganoderma lucidum are beneficial for health. They have been generally consumed as basic food, as they provide plenty of dietary nutrients including fibers, minerals, and vitamins. They are also excellent sources of proteins [4]. Beyond their role as foodstuffs, edible mushrooms feature in certain types of holistic or alternative medicine. G. lucidum, locally known as Lingzhi, is defined as a medicinal mushroom for the prevention of various diseases, as well as for recuperation and health improvement. Ganoderma species are generally found all over the world. Lingzhi exhibits the prevailing features of being an excellent nutrient source of proteins, lipids, and carbohydrates [5]. Lingzhi has been consumed widely in East-Asia as a traditional remedy for centuries [6]. Many of its pharmacological effects have been widely reported such as immune modulation enhancement, soothing the nerves, inflammatory response reduction, cancer growth suppression, cell-aging deceleration, oxidative stress reduction, and anti-aging and lipid accumulation suppressive effects [7,8,9].
Foodstuff-derived protein hydrolysates contain a high level of functional peptides. The dominant features of the protein hydrolysates are their lower molecular weight and relative lack of high-order structure, as well as the increased number of functionally ionizable and exposed hydrophobic groups compared to those of intact proteins. These features denote that their surface interactions, water-solubility, host-receptors, and biological activities might be different from those of proteins. This includes the transduction triggering capability of various signaling pathways, leading to the activation or deactivation of regulators and biological activities above their generic nutritional value [10]. However, the major obstacle in introducing peptides into functional food ingredients is their functional stability during commercial processing and under human physiological conditions [11]. Therefore, functional peptides might partially or completely lose their activity before reaching the target cells or organs [12]. Hence, choosing a delivery system that is highly compatible with human physiological conditions would alleviate this problem.
Liposome encapsulation is a well-known compatibility delivery approach for foodstuff hydrolysates. The advantage of encapsulation within small particles is the stability and bioactivity enhancement of the protein hydrolysates [13]. This approach is suitable for protein and peptide delivery as their molecules possess various polar and non-polar regions similar to their liposome properties [14]. Several studies revealed the potential of liposomal encapsulation of peptides. For example, a pharmacological study of ghrelin, the appetite-stimulating peptide hormone, indicated increasing ghrelin stability and circulation period in the blood [15]. Both the pharmaceutical and cosmetic industries generally use liposome-based carriers to store and deliver functional proteins and peptides for specific purposes [16,17]. Although the use of liposomal encapsulation can be observed in a small number of products in the food industry market, liposomal encapsulation would be a promising approach as its safety and efficiency are proven by the pharmaceutical and food industries.
In this study, we established liposome carriers for protein hydrolysates to enhance the biological activities and stability of the latter. In addition, we also investigated the lipolysis-stimulating activity of the encapsulated Lingzhi protein hydrolysates on 3T3-L1 adipocyte cells. A possible signaling pathway for the encapsulated hydrolysates on the stimulation of lipid breakdown was also investigated using quantitative proteomic analysis. Finally, the possible beneficial mechanisms of the nano-liposomal hydrolysates are clarified and their value as a functional food additive supported.
2. Materials and Methods
2.1. Ganoderma Lucidum Hydrolysate Preparation
Dried Lingzhi (200 g) was powdered using an ultra-centrifugal mill (Retsch Co., Haan, Germany) equipped with a sieve (diameter = 1 mm3) at 8000 rounds per minute (rpm). The powdered mushroom was heated using a modified Pressurized Hot Water Extraction method [18]. Briefly, the Lingzhi was mixed with deionized water at a ratio of 1:2 (w/v) and incubated at 121 °C, 15 psi for 20 min. The extracted Lingzhi was left to cool down and hydrolyzed with pepsin as the first independent factor (X1) at 0.25%, 0.5%, and 1% in 0.1% of HCl for digestion times of 3, 6, and 9 h as the second independent factor (X2) at a constant temperature of 37 °C. Next, the crude was filtrated with a 0.22-µm nylon membrane and fractionated through Vivaspin-20 (GE Healthcare Co., Amersham, UK), with a molecular weight cut-off of 3 kDa. Peptides of <3 kDa were subjected to Solid-Phase Extraction (SPE) (Waters Co., Milford, MA, USA). An amount of 3 mg of small peptides was loaded on an equilibrated SPE column (Sep-Pak C18) and eluted using acetonitrile: water (1:1, v/v). The supernatant was dried using a freeze-drying machine.
2.2. Lingzhi Protein Hydrolysate Optimization by Response Surface Methodology (RSM)
The two independent variable factors used in this study were the digestion time (X1) and the enzyme concentration (X2). The experimental outputs were the degree of hydrolysis (DH) (Y1) and the product yield (Y2). The DH determination was performed according to the method of Nielsen et al. [19] and the product yield was calculated as a percentage of the proteins found in the hydrolysates divided by the raw protein content. While calculating the optimal condition of an independent factor, the values of the other independent factors were fixed. An experimental design was set with 11 conditions, including 9 experimental conditions and 2 central points. The correlation of the independent factors and experimental outputs was used to generate RSM by the following equation:
(1) |
where y is the experimental output; β0 is constant intercept value; βi, βii, and βij are the linear, quadratic, and interaction coefficients, respectively; and xi and xj are the independent variable factors. Three-dimensional response surface plots were drawn to illustrate the correlation between the levels of the process variable factors and the outcome results.
2.3. Nano-Liposome Carrier Preparation and Characterization
Soybean lecithin (Sigma Aldrich Co., St. Louis, MO, USA) and cholesterol (Sigma Aldrich Co., St. Louis, MO, USA) (8:1, w/w) were dissolved in 10 mL of diethyl ether in a 50-mL round bottom flask for 5 min. Once the lipids were thoroughly mixed in diethyl ether, the solvent was removed to yield a lecithin-cholesterol film layer by rotary evaporation (Buchi Co., Flawil, Switzerland) at 100 rpm under reduced pressure. The hydration of the lecithin-cholesterol film layer was accomplished by adding 10 mL of Lingzhi extract and agitating on an orbital shaker at 220 rpm for 6 h at 28 °C to obtain a vesicular white suspension. The vesicular suspension was forced through a membrane filter with a defined pore size of 200 nm by an extruder (GE Healthcare Co., Amersham, UK). After day 7, the loading efficiency of the loaded nanoliposome was determined by a protein-based spectrophotometric analysis. We mixed 100 µL samples of loaded liposomes with 1% Triton X-100 (Sigma Aldrich Co.) and sonicated for 10 min (10 s-interval) to disassemble the liposomes and release the extract. Afterward, the protein content of the clearance solution was assessed by Lowry protein assay using Bovine Serum albumin (Sigma Aldrich Co.) as a reference. The loading efficiency was calculated using the following equation:
Extracted loading Efficiency (w/w) (%) = (protein extracted of which encapsulated in
liposomes (mg) ÷ protein content of extracted Lingzhi (mg)) × 100 | (2) |
The hydrodynamic diameter of the liposomal formulations in deionized water was measured by dynamic light scattering (DLS) using ZetaSizer Nano-ZS (Malvern Instruments, Worcestershire WR, UK), in which the zeta potential was also examined (n = 3).
2.4. Effect of Loaded Nanoliposomes on 3T3-L1 Adipocyte Cells
Cell cytotoxicity of the loaded liposome and unloaded liposome control was evaluated through an MTT assay. Human fibroblasts (American Type Culture Collection., Manassas, VA, USA)) and 3T3-L1 mouse differentiated adipocyte cells (induced by an adipogenic cocktail containing 2.5 mM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, and 10 g/mL insulin for 8 days) were tested for cytotoxicity at various concentrations (104.68, 52.34, 26.17, 13.09, 6.54, 3.27, 1.64, 0.82, 0.41, and 0.20 µg/mL) of loaded liposomes and unloaded liposome as control for 24 h. Next, we measured the optical absorbance at 570 nm using a microplate reader and transformed the results into cell survival rate percentage [20].
The lipolytic effect of the loaded nanoliposome was used to quantify glycerol, a byproduct of lipolysis (EnzyChrom™ Glycerol Assay Kit, BioAssay Systems, Hayward, CA., USA) in cell culture supernatant after 24 h of treatment with the loaded nanoliposome. To determine the intracellular TG content, the differentiated 3T3-L1 cells were treated with the loaded nanoliposomes, as described previously, for 24 h. The cells were washed twice with PBS and fixed with 4% paraformaldehyde for 1 hour at room temperature. Next, the cells were washed once with PBS and isopropanol 60% (v/v), then they were allowed to dry. Next, the cells were stained with 0.5% (v/v) Oil Red O (ORO) (Sigma Aldrich Co.) in an isopropanol solution of 60% for 1 hour. After staining, the unstained dye was removed by rinsing with distilled water. The stained lipid droplets were observed under a stereomicroscope. The stained oil droplets indicating lipid accumulation were solubilized by absolute isopropanol for 15 min and their absorbance was measured at 510 nm using a microplate reader (Multiskan Go, Thermo Scientific, Waltham, MA, USA).
2.5. Proteomic Analysis and Data Processing
To investigate the adipocyte protein expression profiles after the exposure to the loaded liposomes, the cells were lysed by a lysis buffer solution (10 mM HEPES-NaOH pH 8.0 and 0.5% Triton X-100) supplemented with a protease inhibitor cocktail (Thermo Scientific Co.). The supernatant was collected by centrifugation, followed by ice-cold acetone precipitation (1:5 v/v). After precipitation, the protein pellet was reconstituted in 0.2% RapidGest SF (Waters Co.) in 10 mM of Ammonium bicarbonate (Sigma Aldrich Co.). The total protein (50 µg) was subjected to gel-free based digestion. Next, sulfhydryl bond reduction was performed using 5 mM DTT (Sigma Aldrich Co.) in 10 mM ammonium bicarbonate at 72 °C for 1 h and sulfhydryl alkylation using IAA (Sigma Aldrich Co.) at room temperature for 30 min in the dark. The solution was cleaned up using a Desalting Zebra-spin column (Thermo Scientific Co.). The flow-through solution was enzymatically digested by Trypsin (Promega Co., Madison, WI, USA) at a ratio of 1:50 (enzyme: protein) and incubated at 37 °C for 3 h. The digested solution was dried and reconstituted in 0.1% formic acid before being subjected to tandem-mass spectroscopy using a nanoLC-system coupled with high resolution 6600 TripleTOFTM (AB-Sciex, Concord, ON, Canada). The LC conditions were as follows: mobile phase A and B were used, with mobile phase A being composed of 0.1% formic acid in water and mobile phase B comprising 95% acetonitrile with 0.1% formic acid. The LC-method parameters comprised a 135-min long process for a single injection. The analytical column was maintained at 55 °C. Using the data-dependent acquisition mode of mass spectroscopy, the MS scans over a mass range of 400–1600 m/z, selecting the top 20 most abundant peptide ions with charge state in the range of 2–5 (positive mode) for fragmentation. The dynamic exclusion duration was set at 15 s. The raw MS-spectra resulting (.wiff) file was extracted and annotated with protein sequences using the Paragon™ Algorithm by ProteinPilot™ Software [21]. The Mus musculus protein database, retrieved from UniProtKB (16,477 sequences) and used in Paragon™, was assembled in FASTA format and downloaded in May 2021. We set a detected protein threshold of (Unused ProtScore (Conf)) ≥ 0.05 with 1% false discovery rate (FDR) with ≥10 peptides/protein. The protein and peptide comparisons exhibiting >20% coefficient of variation (C.V.) between the replicates were rejected. Both library and SWATH-MS data were imported into SWATHTM processing microapp in PeakView® software. The normalization of the relative protein abundances was performed using the R package, NormalyzerDE [22], in which Quantile-normalization was applied to expression data analysis, after adding 1 to all expression values to avoid errors upon log transformation.
2.6. Statistical Analysis
All experiments were carried out in at least three independent replicates (n = 3), and all data were expressed as the means ± standard deviation. The statistical significance was determined by Duncan’s multiple range test (p-values < 0.05). For the RSM analysis, the generated 3D surface was determined from the fitted polynomial equation, and significant coefficients (p < 0.01) were used in the model. The variance table was generated from both independent variables and experimental outputs using the Design Expert statistical software (version 11.0; State-Ease Inc., Minneapolis, MN, USA). For the pairwise comparisons during the proteomic analysis, we performed One-Way analysis of variance (One-Way ANOVA) at the protein-level analysis with two multiple testing correction methods including the Bonferroni and the Benjamini–Hochberg FDR corrections using the ProteinPilot™ Software.
3. Results
3.1. Lingzhi-Derived Protein Hydrolysate Optimization
The biological activity of the hydrolysates depends on the processing conditions. The activities of various foodstuff hydrolysates were reportedly directly dependent on the degree of hydrolysis, protease activity, and amino acid arrangement [23]. The optimum conditions for the Lingzhi hydrolysate regarding DH and product yield for functional food product manufacturing have not yet been established. Therefore, the present study was aimed at Lingzhi hydrolyzing proteins using RSM to study the effect of the processing conditions including time, enzyme usage on DH, and product yield of the resulting hydrolysates. We applied quadratic analysis statistics to fit an RSM model for independent variable factors. The experimental design using two independent variable factors with two center points (experiment no. 10 and 11) in RSM generation resulted in the observed DH and yield as displayed in Table 1. The RSM generation-related statistical value is shown in Appendix A.
Table 1.
Experiment No. | Independent Factors | Experimental Outputs | ||
---|---|---|---|---|
x1; Time (Hour) | x2; Enzyme (%) | y1; DH (%) | y2; Yield (%) | |
1 | 3 | 0.25 | 28.11 ± 1.03 | 4.16 ± 0.13 |
2 | 3 | 0.50 | 29.83 ± 1.30 | 4.57 ± 0.17 |
3 | 3 | 1.00 | 29.36 ± 1.28 | 4.22 ± 0.15 |
4 | 6 | 0.50 | 33.21 ± 1.03 | 5.25 ± 0.12 |
5 | 6 | 1.00 | 32.91 ± 1.37 | 5.32 ± 0.14 |
6 | 6 | 2.00 | 32.03 ± 0.76 | 5.21 ± 0.22 |
7 | 9 | 0.25 | 33.96 ± 1.14 | 5.58 ± 0.16 |
8 | 9 | 0.50 | 33.17 ± 1.29 | 5.67 ± 0.09 |
9 | 9 | 1.00 | 34.18 ± 1.12 | 5.70 ± 0.20 |
10 | 6 | 0.50 | 33.16 ± 0.58 | 5.24 ± 0.09 |
11 | 6 | 0.50 | 32.92 ± 0.32 | 5.21 ± 0.13 |
As outputs from the overall experimental design, the DH and product yield ranged from 28.11% ± 1.03% to 34.18% ± 1.12% and 4.16% ± 0.13% to 5.70% ± 0.20%, respectively. The difference in the DH and yield could be due to the difference in the digestion time and enzyme concentration. The equation for multiple regression analysis during the RMS was performed to resolve the coefficients of the independent factors of the linear (x1, x2), quadratic (x12, x22), and two-factor relation (x1×2) to fit the RSM. According to the multiple regression analysis, the explanatory model equation of the DH (y1) and percentage of product yield (y2) is given as follows in Table 2.
Table 2.
Responding | Quadratic Model | R 2 | p-Value |
---|---|---|---|
y1 | y1 = 33.14 + 2.08x1 − 0.497x2 − 0.283x1x2 − 1.53x12 − 0.635x22 | 0.96 | 0.0019 |
y2 | y2 = 5.293 + 0.726x1 − 0.027x2 − 0.066x1x2 − 0.264x12 − 0.073x22 | 0.97 | 0.0010 |
The total coefficient value (R2) was used to imply the model suitability. The R2 of the DH and the product % yield were 0.958 and 0.968, respectively. This result indicated that the variation in the experimental data was lower than 5% (within 95% level of confidence). The 3-dimensional response model surfaces (3D-RMS) for each variable are illustrated in Figure 1.
The experimental outputs of the processing related to both independent factors, DH (Figure 1A) and % yield (Figure 1B) indicating that the hydrolysate processing depended on the digestion time and enzyme usage. The 3D-RMS for the DH of hydrolysate as a function of digestion time, at fixed enzyme usage, revealed that DH was dependent on the digestion time. Also, DH increased with enzyme usage at the fixed digestion time, suggesting that DH was also dependent on the enzyme usage. Yield also had correlative results, dependent on the digestion time and enzyme usage. In order to obtain the highest DH and product yield, the RSM model was optimized by setting the highest value of response variable factors. As a result, X1 was 8.63 h and X2 was 0.93%, and the highest values of y1 and y2 were 33.99% and 5.70%, respectively. These characteristics of DH and yield curves were associated with feedback inhibition during the hydrolysis, where products may act as an inhibitor to protease [24]. The curves strongly suggested that the processing at different conditions and factors were involved. The independent factors, both time and enzyme concentration, had the optimum range for hydrolysate production to gain the maximum DH and yield. To endorse the reliability and validity of the model for processing, the assays were performed under those optimal conditions. The actual experimental values for DH and product yield were 32.71 ± 0.17% and 5.44 ± 0.14%, respectively; the experimental values fitted with the values that were predicted by the model within a 95% confidence interval. These results confirmed that the model was suitable for Lingzhi protein hydrolysate processing for use as functional ingredients regarding cost- and time-efficiency.
3.2. Encapsulation Efficiency and Loaded Liposome Size, Polydispersity Index, and Zeta Potential
The encapsulation efficiency of the liposomal formulation was estimated. The liposomes would passively entrap the protein hydrolysate in their hydrophilic region. However, many factors influence the entrapping efficiency such as lipid molar ratios, molecular size, charge, and molecule stability. To evaluate the entrapping efficiency, we used a non-ionic detergent, Triton X-100, as a neutral detergent to disrupt the liposome shell structure, thereby allowing the leakage of the encapsulated Lingzhi protein hydrolysate [25]. Based on the encapsulation condition, 61.24 ± 3.18% of the encapsulation efficiency was achieved. The encapsulation efficiency showed that the liposomal preparation for protein hydrolysate moderates the encapsulated level. The protein hydrolysate has a mixture of peptides with a variety of molecular weights, sizes, charges, and structures. Middle-sized peptides might interact with the lipid layer and form an oligomerization structure like a beta-barrel. This could disrupt the entrapped protein hydrolysate inside the core structure of the liposome [26]. Another reason was the fluctuation in electrostatic interaction between the charges of various peptides and the liposome surface, which might negatively affect the encapsulation efficiency.
The diameter of the nanoliposome in the closest realistic physiological condition was determined. Dynamic light scattering (DLS) analysis showed loaded liposome diameters in the PBS solution were at 149.84 ± 0.58 nm (Figure S1). Low polydispersity index (PdI) of =0.048 ± 0.014 supported that particles were monodispersed. In addition, the low PdI value also reflected that the particle exhibits a narrow size distribution, providing a very high surface area that would be ideal for the correct order. This evidence suggested the homogeneity of the loaded liposome. The overall charge of loaded liposomes was neutral. Zeta (ζ)-potential of the loaded liposome was −3.75 ± 0.25 mV (Figure S2). This could suggest that the overall structure of the liposome exhibited neutral charge particle, due to the value of ζ-potential ranging from −10 to +10 mV, is considered neutral [27]. The hydrodynamic size of the loaded liposome was roughly 140 nm, indicating that the liposome was characterized in the nanoscale. As the efficiency of cellular uptake relates to the particle size, a small particle size of around 100–160 nm would have great potential for cellular uptake into the blood steam via clathrin-dependent mechanisms [28]. Beneficial properties of the negative value of ζ-potential were particle stability under physiological conditions and the prevention of cellular fusion and aggression of phagocytosis, responding less than the positive value of ζ-potential [29]. Therefore, the hydrodynamics of loaded liposome size and negative ζ-potential are the two key criteria that have been considered for various applications.
3.3. Effect of Loaded Nanoliposome on 3T3-L1 Adipocyte Cells
The safety of using the loaded liposomes is a crucial factor for establishing commercialized products. Therefore, we investigated cell cytotoxicity to evaluate the safety of loaded liposomes using human fibroblasts as normal cell controls and the differentiated 3T3-L1 adipocyte cell line as a lipid storage cell model. Cell viability was measured through an MTT assay and illustrated in Figure 2.
As a result, the loaded liposomes did not significantly affect the viability of either cell lines at concentrations up to 52.34 μg/mL. However, a further increment (104.68 μg/mL) resulted in slight cytotoxic effects on the fibroblast cells. Therefore, we considered the cytotoxicity-related no-observed-adverse-effect level of the loaded liposomes was 52.34 μg/mL for further experiments. Oral delivery of liposomal protein and peptide is the easy and convenient route. The liposome particles made by cholesterol and lecithin were moderately stable (~80% stability measured by particle leakage) in gastric environment (pH 2) at 37 °C at 1 h and stable (~95% stability measured by particle leakage) in pancreatin [30]. These results indicate that our liposome formulations may be suitable as oral delivery particles due to their stable behavior through the oral route. As the potential application of the loaded liposome would be in functional food ingredients, this concentration was used in the determination of lipolysis activity and proteomics.
The lipolysis process is a metabolic process that breaks down TGs to free fatty acid (FA) and glycerol. It controls the energy homeostasis by regulating the breakdown of TGs [31]. Therefore, the effect of 52.34 μg/mL loaded liposome on the TG breakdown in adipocyte cells was investigated through the measurement of glycerol released into the medium culture. In the present study, the loaded liposome significantly increased glycerol release and reduced lipid accumulation. The loaded nanoliposome affected the adipocytes by inducing the TG breakdown, as we observed the release of glycerol at 1.63 ± 0.25-fold greater than that in the control (p < 0.01). The intracellular lipid exposed by the loaded nanoliposome was visualized by ORO staining where the lower staining intensity represented the lower lipid accumulation (Figure 3).
The ORO staining demonstrated lower intracellular lipid accumulation in cells exposed to loaded liposomes compared to the control. The loaded liposome increased glycerol release corresponding to 50% release at 13.085 µg/mL. ORO staining revealed the most pronounced TG clearance at a peak concentration (52.34 µg/mL), with lower staining severity representing lower lipid aggregation (Figure 3). This evidence implied that the loaded nanoliposomes were able to reduce the lipid accumulation as determined by the reduced ORO staining level and the free glycerol level increase. Therefore, we next applied a label-free proteomics approach to study the molecular mechanisms of lipid breakdown activity that could potentially lead to the reduced lipid accumulation in the adipocytes for a better understanding of the loaded liposome-induced lipolytic pathways.
3.4. Quantitative Proteomic Analysis
We used a proteomics approach to investigate the signaling pathways that could be potentially affected by the loaded liposomes in the adipocyte cells. The LC-MS/MS analysis revealed a total number of 3425 proteins among the loaded liposome and the control groups. The interpretation of the quantitative proteomics and bioinformatics data showed that 439 proteins were affected by the loaded liposomes as shown in Figure 4. Although we used differentiated adipocytes from mice, this was a widely accepted cell-based model [32]. The raw data from the LC-MS/MS analysis showed a small difference in the total ion count between each LC-MS injection. Therefore, data normalization of the raw dataset was strongly required prior to further analysis. After the log transformation and VSN normalization, pooled intragroup median absolute deviation (PMAD) of the identified proteins among replicates was lower than 0.22 (Control and loaded liposomes n = 3 and 3, respectively; Figure S3). In general, a PMAD value of ≤0.3 was accepted as the superior precision dataset [33]. According to the normalized proteomic analysis, the volcano plot of the differential protein expression identifying the most significant protein expression changes is depicted in Figure 4. Each spot represents the protein expression ratio (loaded liposome: control) according to their log10 p-values. The differentially expressed proteins associated with these spots are listed in the proteomics table (Appendix B).
We identified four significantly different proteins, compared between the loaded liposome and control groups. The global protein expression changes were mostly down-regulated (79.37%; for 350 of 441 proteins). Specifically, three significantly different proteins (p < 0.05 and −4 > log2 (fold change) > 4) were down-regulated (green region, Figure 4) whereas one was up-regulated (red region, Figure 3). Considering the biological functions of the significantly different proteins, the down-regulated ones were Testis-specific serine/threonine-protein kinase 5 (TSSK5_MOUSE), WD40 repeat-containing protein SMU1 (SMU1_MOUSE), and metabotropic glutamate receptor 7 (GRM7_MOUSE), whereas the up-regulated one was Kinesin light chain 4 (KLC4_MOUSE). The detailed description and function of these proteins are presented in Table 3.
Table 3.
Accession | Protein Name | Biological Process |
---|---|---|
TSSK5_MOUSE | Testis-specific serine/threonine-protein kinase 5 | Cell differentiation, intracellular signal transduction, multicellular organism development, protein phosphorylation, and spermatogenesis |
SMU1_MOUSE | WD40 repeat-containing protein SMU1 | mRNA splicing, via spliceosome, regulation of alternative mRNA splicing, via spliceosome, and RNA splicing |
GRM7_MOUSE | Metabotropic glutamate receptor 7 | adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway, chemical synaptic transmission, and regulation of neuron death |
KLC4_MOUSE | Kinesin light chain 4 | - |
The biological functions of these proteins were variable, including cell differentiation, intracellular signal transduction, organism development, protein phosphorylation, spermatogenesis, mRNA splicing, cAMP-related G protein inhibition, chemical synapsis-related activities, and the regulation of neuronal death. Notably, the liposome-encapsulated protein hydrolysates affected the 3T3-L1 cells in various biological functions beyond lipolysis.
Although these significant proteins were not directly associated with lipolysis, differentially expressed proteins in lipid biosynthesis and lipolysis could also be identified. Our investigation detected that fatty acid synthase (FAS; FAS_MOUSE), the major actor of lipogenesis, was suppressed more than 5-fold (log2 fold change as 2.35) in the loaded liposome group (supplementary data 2). The lipogenesis works via FAS to synthesize the long-chain FA from acetyl-CoA, malonyl-CoA, and NADPH. Hence, FAS downregulation could imply that cellular lipogenesis might be reduced due to the decrease in its abundance and activity. FAS-down regulation, an increased rate of lipolysis, and TG release could lead to a net TG loss on the cellular level. Moreover, another protein that elongates the long-chain fatty acids, protein 5 (ELOV5_MOUSE), was also down-regulated. Elov5, known as PUFA elongase, is a major PPARα-regulated enzyme functioning in monounsaturated and polyunsaturated fatty acid synthesis [34].
4. Conclusions
The concordance between the proteomics results and the cellular lipidemic activity could imply that the Lingzhi protein hydrolysate-loaded nano-liposomes induced cellular lipolysis without affecting cell viability. The proteomic study also indicated that loaded liposomes exhibited lipid accumulation with the suppression of FAS and ELOV5. Finally, other proteins including TSSK5, SMU1, GRM7_MOUSE, and KLC4, were identified in the loaded liposome treatment group, associated with various biological mechanisms beyond lipid metabolism. Therefore, the nano-liposomal hydrolysates might serve as novel functional ingredients in the treatment and prevention of obesity.
Acknowledgments
This research project was supported by National Research Council of Thailand (NRCT): NRCT5-RGJ63002-042. Additional support for core research facilities was provided by faculty of pharmacy, Chiang-Mai university.
Supplementary Materials
The following are available online at https://www.mdpi.com/article/10.3390/foods10092157/s1, Figure S1: DLS analysis showed size distribution, Figure S2: DLS analysis showed zeta-potential distribution, Figure S3: Intragroup variation analysis.
Appendix A
Table A1.
1. DH | ||||||
Model | 39.47 | 5 | 7.89 | 22.9 | 0.0019 | significant |
A-Time | 4.68 | 1 | 4.68 | 13.56 | 0.0143 | |
B-Enzyme | 0.769 | 1 | 0.769 | 2.23 | 0.1955 | |
AB | 0.083 | 1 | 0.083 | 0.2407 | 0.6445 | |
A² | 5.7 | 1 | 5.7 | 16.54 | 0.0097 | |
B² | 1.06 | 1 | 1.06 | 3.06 | 0.1405 | |
Residual | 1.72 | 5 | 0.3447 | |||
Lack of Fit | 1.68 | 3 | 0.5585 | 23.24 | 0.0415 | significant |
Pure Error | 0.0481 | 2 | 0.024 | |||
Cor Total | 41.19 | 10 | ||||
Std. Dev. | 0.5871 | R² | 0.9582 | |||
Mean | 32.08 | Adjusted R² | 0.9163 | |||
C.V. % | 1.83 | Predicted R² | 0.4581 | |||
Adeq Precision | 11.99244 | |||||
2. Yield | ||||||
Model | 2.87 | 5 | 0.5747 | 30.13 | 0.001 | significant |
A-Time | 0.5672 | 1 | 0.5672 | 29.74 | 0.0028 | |
B-Enzyme | 0.0023 | 1 | 0.0023 | 0.1184 | 0.7448 | |
AB | 0.0046 | 1 | 0.0046 | 0.2399 | 0.645 | |
A² | 0.1691 | 1 | 0.1691 | 8.87 | 0.0309 | |
B² | 0.0139 | 1 | 0.0139 | 0.7302 | 0.4318 | |
Residual | 0.0954 | 5 | 0.0191 | |||
Lack of Fit | 0.0945 | 3 | 0.0315 | 72.69 | 0.0136 | significant |
Pure Error | 0.0009 | 2 | 0.0004 | |||
Cor Total | 2.97 | 10 | ||||
Std. Dev. | 0.1381 | R² | 0.9679 | |||
Mean | 5.1 | Adjusted R² | 0.9358 | |||
C.V. % | 2.71 | Predicted R² | −0.5277 | |||
Adeq Precision | 14.0722 |
Appendix B
Table A2.
Protein Name | p-Value | Log2 Intensity | ||||||
---|---|---|---|---|---|---|---|---|
Control01 | Control02 | Control03 | Liposome01 | Liposome02 | Liposome03 | log(p-Value) | ||
HNRH1_MOUSE | 3.65 × 10−6 | 16.58 | 16.46 | 16.41 | 14.17 | 14.23 | 14.26 | 5.44 |
VIME_MOUSE | 9.17 × 10−6 | 19.58 | 19.48 | 19.52 | 17.64 | 17.55 | 17.70 | 5.04 |
TBA8_MOUSE | 1.06 × 10−5 | 19.94 | 19.82 | 19.70 | 17.87 | 17.87 | 17.90 | 4.98 |
HIG1A_MOUSE | 1.72 × 10−5 | 13.17 | 13.12 | 12.98 | 11.23 | 11.27 | 11.04 | 4.76 |
UBA1_MOUSE | 1.80 × 10−5 | 17.44 | 17.45 | 17.35 | 15.74 | 15.70 | 15.54 | 4.75 |
IF4A1_MOUSE | 1.96 × 10−5 | 16.22 | 16.32 | 16.30 | 14.65 | 14.57 | 14.71 | 4.71 |
KPYM_MOUSE | 2.20 × 10−5 | 20.80 | 21.00 | 20.79 | 18.90 | 19.10 | 18.83 | 4.66 |
PSMD2_MOUSE | 2.24 × 10−5 | 15.41 | 15.44 | 15.06 | 12.99 | 13.21 | 13.17 | 4.65 |
TBA4A_MOUSE | 2.42 × 10−5 | 20.35 | 20.20 | 20.09 | 18.36 | 18.42 | 18.53 | 4.62 |
ATPA_MOUSE | 3.24 × 10−5 | 18.45 | 18.15 | 18.20 | 16.13 | 16.46 | 16.29 | 4.49 |
IPO5_MOUSE | 3.30 × 10−5 | 15.47 | 15.28 | 15.53 | 13.84 | 13.79 | 13.80 | 4.48 |
RAN_MOUSE | 3.41 × 10−5 | 18.54 | 18.40 | 18.76 | 16.53 | 16.64 | 16.78 | 4.47 |
RANT_MOUSE | 3.41 × 10−5 | 18.54 | 18.40 | 18.76 | 16.53 | 16.64 | 16.78 | 4.47 |
RGL2_MOUSE | 3.44 × 10−5 | 15.83 | 15.62 | 15.75 | 13.64 | 13.99 | 13.91 | 4.46 |
MYH9_MOUSE | 3.81 × 10−5 | 17.63 | 17.64 | 17.86 | 15.73 | 15.94 | 16.04 | 4.42 |
ADT2_MOUSE | 4.25 × 10−5 | 18.79 | 19.10 | 18.81 | 16.78 | 17.10 | 16.74 | 4.37 |
ADT1_MOUSE | 4.37 × 10−5 | 18.12 | 18.30 | 18.16 | 16.21 | 16.60 | 16.37 | 4.36 |
RHOA_MOUSE | 4.43 × 10−5 | 15.32 | 15.23 | 15.38 | 13.93 | 13.79 | 13.77 | 4.35 |
GLRX3_MOUSE | 4.53 × 10−5 | 16.10 | 16.22 | 15.99 | 14.55 | 14.36 | 14.56 | 4.34 |
FLNA_MOUSE | 4.90 × 10−5 | 17.85 | 18.20 | 18.00 | 16.40 | 16.38 | 16.38 | 4.31 |
SYSC_MOUSE | 4.95 × 10−5 | 12.81 | 13.18 | 12.30 | 9.98 | 10.00 | 9.94 | 4.31 |
SDHA_MOUSE | 5.34 × 10−5 | 15.09 | 14.78 | 15.07 | 13.39 | 13.18 | 13.18 | 4.27 |
PRS6B_MOUSE | 5.61 × 10−5 | 15.29 | 15.71 | 15.39 | 13.70 | 13.69 | 13.52 | 4.25 |
CAN2_MOUSE | 5.62 × 10−5 | 12.78 | 13.08 | 12.52 | 10.78 | 10.59 | 10.80 | 4.25 |
ATAD1_MOUSE | 5.75 × 10−5 | 16.37 | 16.22 | 15.98 | 14.27 | 14.20 | 13.83 | 4.24 |
RS2_MOUSE | 6.36 × 10−5 | 16.51 | 16.43 | 16.18 | 14.73 | 14.83 | 14.62 | 4.20 |
NONO_MOUSE | 6.55 × 10−5 | 15.03 | 15.20 | 15.10 | 13.09 | 12.32 | 12.58 | 4.18 |
PGM1_MOUSE | 6.58 × 10−5 | 15.08 | 15.23 | 15.20 | 13.77 | 13.89 | 13.85 | 4.18 |
EF2_MOUSE | 6.83 × 10−5 | 19.20 | 19.04 | 19.08 | 17.60 | 17.80 | 17.57 | 4.17 |
FINC_MOUSE | 6.87 × 10−5 | 16.44 | 16.08 | 16.53 | 14.48 | 14.55 | 14.63 | 4.16 |
K22O_MOUSE | 7.50 × 10−5 | 15.65 | 15.76 | 14.98 | 18.79 | 19.12 | 18.30 | 4.13 |
TCPB_MOUSE | 8.00 × 10−5 | 15.64 | 15.75 | 15.50 | 14.27 | 14.01 | 14.12 | 4.10 |
SYVC_MOUSE | 8.03 × 10−5 | 13.57 | 14.21 | 13.62 | 11.53 | 11.61 | 11.32 | 4.10 |
PRDX2_MOUSE | 8.32 × 10−5 | 16.59 | 16.25 | 16.50 | 14.71 | 14.65 | 14.95 | 4.08 |
SERPH_MOUSE | 8.67 × 10−5 | 17.83 | 18.03 | 17.99 | 16.55 | 16.70 | 16.54 | 4.06 |
APT_MOUSE | 8.76 × 10−5 | 13.68 | 13.87 | 14.07 | 11.55 | 12.03 | 11.42 | 4.06 |
MYH10_MOUSE | 8.77 × 10−5 | 14.63 | 14.66 | 14.52 | 11.93 | 12.05 | 12.69 | 4.06 |
HS90A_MOUSE | 9.32 × 10−5 | 19.67 | 19.82 | 19.74 | 18.19 | 18.48 | 18.32 | 4.03 |
EIF3E_MOUSE | 0.000109 | 12.02 | 13.07 | 13.27 | 8.21 | 9.18 | 8.62 | 3.96 |
COF1_MOUSE | 0.000111 | 20.53 | 20.48 | 20.50 | 19.26 | 19.40 | 19.20 | 3.95 |
TBB5_MOUSE | 0.000112 | 18.99 | 18.79 | 18.92 | 17.67 | 17.69 | 17.69 | 3.95 |
TBA1C_MOUSE | 0.000112 | 21.61 | 21.08 | 21.35 | 19.63 | 19.46 | 19.68 | 3.95 |
RL6_MOUSE | 0.000116 | 14.96 | 14.92 | 14.97 | 13.88 | 13.76 | 13.76 | 3.94 |
TBA1B_MOUSE | 0.000118 | 21.62 | 21.10 | 21.37 | 19.64 | 19.50 | 19.72 | 3.93 |
TBB4B_MOUSE | 0.000118 | 18.99 | 18.77 | 18.91 | 17.62 | 17.68 | 17.68 | 3.93 |
TBA1A_MOUSE | 0.000122 | 21.32 | 20.84 | 21.12 | 19.51 | 19.37 | 19.53 | 3.91 |
TERA_MOUSE | 0.000125 | 19.24 | 19.22 | 19.26 | 18.07 | 18.18 | 18.12 | 3.90 |
PP1B_MOUSE | 0.000129 | 16.74 | 16.73 | 16.63 | 15.62 | 15.53 | 15.55 | 3.89 |
K1C15_MOUSE | 0.000132 | 15.09 | 14.81 | 14.93 | 16.24 | 16.17 | 16.23 | 3.88 |
K1C17_MOUSE | 0.000132 | 15.09 | 14.81 | 14.93 | 16.24 | 16.17 | 16.23 | 3.88 |
ATPB_MOUSE | 0.000137 | 19.50 | 19.44 | 19.37 | 18.08 | 18.18 | 18.33 | 3.86 |
HS90B_MOUSE | 0.000139 | 20.21 | 20.04 | 20.30 | 18.75 | 18.97 | 18.77 | 3.86 |
IF4G1_MOUSE | 0.000144 | 13.62 | 13.50 | 13.27 | 11.78 | 11.10 | 11.33 | 3.84 |
CPSF5_MOUSE | 0.000148 | 14.38 | 14.59 | 14.62 | 13.23 | 13.35 | 13.31 | 3.83 |
MYADM_MOUSE | 0.000151 | 13.23 | 13.16 | 13.01 | 11.29 | 10.72 | 10.41 | 3.82 |
S35E3_MOUSE | 0.000152 | 12.63 | 13.06 | 12.52 | 11.02 | 11.11 | 11.07 | 3.82 |
PUR6_MOUSE | 0.000153 | 18.17 | 17.71 | 17.96 | 15.97 | 16.31 | 15.75 | 3.82 |
ANXA2_MOUSE | 0.000156 | 20.59 | 20.84 | 20.61 | 19.12 | 19.44 | 19.25 | 3.81 |
RS3_MOUSE | 0.000157 | 18.82 | 18.55 | 18.71 | 16.61 | 16.87 | 16.09 | 3.81 |
PDIA1_MOUSE | 0.000158 | 20.30 | 20.30 | 20.23 | 18.96 | 19.21 | 19.09 | 3.80 |
HNRPF_MOUSE | 0.00016 | 16.04 | 15.88 | 16.21 | 14.59 | 14.28 | 14.65 | 3.79 |
FLNB_MOUSE | 0.000165 | 16.61 | 16.89 | 16.76 | 15.53 | 15.25 | 15.21 | 3.78 |
LDHA_MOUSE | 0.000169 | 19.05 | 19.17 | 19.18 | 17.69 | 18.00 | 17.67 | 3.77 |
RL11_MOUSE | 0.000175 | 17.54 | 17.32 | 17.35 | 15.90 | 16.21 | 15.90 | 3.76 |
FLNC_MOUSE | 0.000184 | 16.60 | 16.87 | 16.57 | 15.41 | 15.23 | 15.42 | 3.74 |
MVP_MOUSE | 0.000184 | 15.70 | 15.74 | 15.43 | 13.92 | 13.14 | 13.40 | 3.73 |
HSP7C_MOUSE | 0.000191 | 19.22 | 19.02 | 18.99 | 17.98 | 17.88 | 17.86 | 3.72 |
ALDOA_MOUSE | 0.000206 | 18.40 | 18.48 | 18.51 | 17.48 | 17.40 | 17.39 | 3.69 |
PP1G_MOUSE | 0.000222 | 16.26 | 16.32 | 16.27 | 15.30 | 15.05 | 15.16 | 3.65 |
PP1A_MOUSE | 0.000222 | 16.26 | 16.32 | 16.27 | 15.30 | 15.05 | 15.16 | 3.65 |
PSMD5_MOUSE | 0.000233 | 15.59 | 15.92 | 15.73 | 14.00 | 14.46 | 14.11 | 3.63 |
PROF1_MOUSE | 0.000243 | 20.22 | 19.93 | 19.78 | 18.46 | 18.31 | 18.66 | 3.61 |
XPO2_MOUSE | 0.000262 | 12.68 | 12.49 | 12.25 | 10.12 | 10.52 | 9.52 | 3.58 |
LMNA_MOUSE | 0.00027 | 16.59 | 16.69 | 16.44 | 15.47 | 15.54 | 15.47 | 3.57 |
TDRD1_MOUSE | 0.000295 | 13.59 | 13.62 | 13.36 | 15.73 | 15.45 | 14.98 | 3.53 |
TIF1B_MOUSE | 0.000299 | 16.56 | 16.31 | 16.41 | 15.27 | 15.25 | 14.94 | 3.52 |
RPN2_MOUSE | 0.000314 | 15.97 | 16.00 | 16.01 | 13.80 | 12.59 | 13.57 | 3.50 |
HNRPU_MOUSE | 0.000319 | 17.21 | 17.24 | 17.36 | 14.85 | 15.72 | 15.38 | 3.50 |
RL18A_MOUSE | 0.000329 | 14.71 | 14.44 | 14.93 | 13.18 | 12.89 | 13.32 | 3.48 |
ERO1A_MOUSE | 0.000386 | 15.67 | 15.38 | 15.62 | 14.37 | 14.48 | 14.54 | 3.41 |
TCPZ_MOUSE | 0.000399 | 16.61 | 16.71 | 16.55 | 14.43 | 14.60 | 13.47 | 3.40 |
SCMC1_MOUSE | 0.00041 | 14.28 | 14.38 | 14.72 | 13.11 | 13.18 | 12.81 | 3.39 |
TM183_MOUSE | 0.00044 | 15.32 | 15.38 | 15.66 | 16.48 | 16.56 | 16.60 | 3.36 |
HSP74_MOUSE | 0.000448 | 15.18 | 15.18 | 15.29 | 13.44 | 13.68 | 14.09 | 3.35 |
SMD1_MOUSE | 0.000461 | 16.87 | 16.91 | 17.00 | 15.65 | 15.81 | 16.02 | 3.34 |
CH10_MOUSE | 0.000468 | 16.69 | 16.69 | 16.73 | 15.41 | 15.80 | 15.57 | 3.33 |
UGDH_MOUSE | 0.000477 | 14.07 | 14.57 | 13.84 | 11.66 | 10.55 | 11.72 | 3.32 |
CAP1_MOUSE | 0.000498 | 16.30 | 16.31 | 16.47 | 14.58 | 15.23 | 14.87 | 3.30 |
ENPL_MOUSE | 0.000579 | 18.40 | 18.37 | 18.66 | 17.38 | 17.53 | 17.48 | 3.24 |
K1C10_MOUSE | 0.000616 | 19.19 | 18.83 | 19.03 | 19.97 | 20.10 | 20.12 | 3.21 |
2AAB_MOUSE | 0.000622 | 16.25 | 16.35 | 16.31 | 15.06 | 15.08 | 15.45 | 3.21 |
IF5A1_MOUSE | 0.000629 | 19.07 | 18.46 | 18.51 | 17.27 | 17.30 | 17.22 | 3.20 |
GDIR1_MOUSE | 0.000645 | 18.34 | 18.29 | 18.31 | 17.37 | 17.53 | 17.51 | 3.19 |
AATM_MOUSE | 0.000648 | 17.71 | 17.39 | 17.46 | 16.14 | 16.46 | 16.46 | 3.19 |
RTN4_MOUSE | 0.000686 | 18.65 | 18.56 | 18.47 | 17.45 | 17.67 | 17.70 | 3.16 |
IMA3_MOUSE | 0.000702 | 14.57 | 14.31 | 14.34 | 13.11 | 12.85 | 13.40 | 3.15 |
VINC_MOUSE | 0.000715 | 15.15 | 15.11 | 15.34 | 14.37 | 14.18 | 14.12 | 3.15 |
IPO9_MOUSE | 0.000716 | 13.49 | 13.79 | 13.48 | 9.63 | 10.70 | 11.33 | 3.15 |
PTBP1_MOUSE | 0.000751 | 16.80 | 16.77 | 16.35 | 15.15 | 15.03 | 14.37 | 3.12 |
TCPE_MOUSE | 0.000793 | 15.29 | 15.48 | 15.26 | 12.43 | 13.52 | 13.49 | 3.10 |
ROA2_MOUSE | 0.000823 | 17.53 | 17.74 | 17.68 | 16.65 | 16.82 | 16.47 | 3.08 |
DYH17_MOUSE | 0.000832 | 15.79 | 15.55 | 16.03 | 16.81 | 17.02 | 17.08 | 3.08 |
CLH1_MOUSE | 0.000871 | 16.53 | 16.87 | 16.48 | 15.33 | 15.18 | 14.61 | 3.06 |
PDIA6_MOUSE | 0.0009 | 17.40 | 17.61 | 17.45 | 16.51 | 16.69 | 16.65 | 3.05 |
TCPH_MOUSE | 0.000902 | 15.71 | 15.81 | 15.83 | 14.01 | 14.55 | 14.69 | 3.04 |
TSN_MOUSE | 0.000904 | 13.78 | 14.16 | 13.83 | 12.71 | 12.19 | 11.89 | 3.04 |
BIP_MOUSE | 0.000924 | 19.73 | 19.42 | 19.53 | 18.43 | 18.63 | 18.67 | 3.03 |
ARP2_MOUSE | 0.000936 | 13.07 | 13.22 | 12.74 | 11.18 | 9.70 | 10.44 | 3.03 |
AP2B1_MOUSE | 0.000944 | 13.83 | 13.51 | 14.01 | 12.35 | 11.43 | 11.32 | 3.02 |
DDX3X_MOUSE | 0.001 | 14.39 | 14.57 | 14.65 | 13.03 | 11.91 | 12.73 | 3.00 |
ALBU_MOUSE | 0.001032 | 17.91 | 17.81 | 17.73 | 16.88 | 17.06 | 17.03 | 2.99 |
RSSA_MOUSE | 0.001081 | 18.25 | 18.16 | 18.23 | 17.10 | 17.49 | 17.15 | 2.97 |
2AAA_MOUSE | 0.001131 | 16.75 | 16.82 | 16.86 | 15.95 | 16.02 | 16.14 | 2.95 |
CATB_MOUSE | 0.001131 | 15.43 | 15.32 | 15.81 | 14.43 | 14.49 | 14.20 | 2.95 |
NNRE_MOUSE | 0.001157 | 11.06 | 10.70 | 11.31 | 9.55 | 9.59 | 9.94 | 2.94 |
TBB2B_MOUSE | 0.001168 | 18.07 | 17.91 | 18.20 | 17.23 | 17.25 | 17.22 | 2.93 |
TBB2A_MOUSE | 0.001168 | 18.07 | 17.91 | 18.20 | 17.23 | 17.25 | 17.22 | 2.93 |
ACTN4_MOUSE | 0.001328 | 17.08 | 16.94 | 17.30 | 16.31 | 16.09 | 16.14 | 2.88 |
ERO1B_MOUSE | 0.001349 | 14.30 | 13.93 | 14.27 | 12.28 | 12.63 | 13.09 | 2.87 |
6PGL_MOUSE | 0.001531 | 15.37 | 15.81 | 15.86 | 14.54 | 14.71 | 14.65 | 2.81 |
RAP1B_MOUSE | 0.001542 | 15.48 | 15.07 | 15.33 | 14.30 | 13.64 | 14.04 | 2.81 |
RAP1A_MOUSE | 0.001542 | 15.48 | 15.07 | 15.33 | 14.30 | 13.64 | 14.04 | 2.81 |
ANXA6_MOUSE | 0.001692 | 16.80 | 16.23 | 16.23 | 15.02 | 15.16 | 15.38 | 2.77 |
S10AB_MOUSE | 0.001703 | 13.22 | 13.31 | 14.28 | 15.26 | 15.56 | 15.45 | 2.77 |
PPIB_MOUSE | 0.001762 | 15.44 | 15.65 | 15.39 | 14.45 | 14.78 | 14.62 | 2.75 |
H14_MOUSE | 0.00179 | 17.02 | 16.91 | 17.20 | 17.87 | 18.00 | 17.75 | 2.75 |
API5_MOUSE | 0.001801 | 14.71 | 14.07 | 14.21 | 12.94 | 13.28 | 13.09 | 2.74 |
MDGA1_MOUSE | 0.001891 | 19.07 | 18.32 | 17.69 | 16.43 | 15.32 | 15.80 | 2.72 |
SRPRA_MOUSE | 0.001922 | 13.29 | 12.49 | 12.48 | 10.53 | 11.16 | 9.90 | 2.72 |
FKB1A_MOUSE | 0.001939 | 13.86 | 13.87 | 14.02 | 13.22 | 12.72 | 12.76 | 2.71 |
CDC42_MOUSE | 0.001946 | 17.24 | 17.13 | 17.09 | 14.77 | 15.74 | 15.80 | 2.71 |
FAS_MOUSE | 0.002116 | 13.77 | 13.67 | 14.08 | 10.58 | 12.16 | 11.74 | 2.67 |
PLAK_MOUSE | 0.002129 | 14.54 | 14.51 | 14.25 | 13.56 | 13.25 | 12.85 | 2.67 |
MDHM_MOUSE | 0.002326 | 20.02 | 20.21 | 20.00 | 19.18 | 19.44 | 19.34 | 2.63 |
ANXA1_MOUSE | 0.002341 | 16.96 | 16.78 | 17.14 | 15.77 | 16.14 | 16.13 | 2.63 |
PLCB1_MOUSE | 0.002343 | 17.38 | 17.61 | 17.54 | 16.79 | 16.68 | 16.88 | 2.63 |
KAP0_MOUSE | 0.002469 | 13.88 | 14.01 | 13.80 | 12.76 | 11.66 | 12.46 | 2.61 |
RAGP1_MOUSE | 0.00262 | 14.51 | 14.81 | 14.25 | 13.50 | 12.75 | 12.53 | 2.58 |
BIRC2_MOUSE | 0.002678 | 16.61 | 15.81 | 16.19 | 17.24 | 17.66 | 17.66 | 2.57 |
MOES_MOUSE | 0.002759 | 15.45 | 15.26 | 15.56 | 13.43 | 14.44 | 13.37 | 2.56 |
KAD2_MOUSE | 0.003069 | 13.79 | 14.07 | 13.67 | 12.41 | 12.90 | 11.92 | 2.51 |
R51A1_MOUSE | 0.0031 | 12.95 | 13.00 | 13.56 | 11.02 | 12.05 | 11.58 | 2.51 |
RS7_MOUSE | 0.003174 | 17.66 | 16.56 | 16.77 | 15.44 | 15.54 | 15.31 | 2.50 |
RLA0_MOUSE | 0.0033 | 18.50 | 18.44 | 17.93 | 16.74 | 17.30 | 17.22 | 2.48 |
K2C1_MOUSE | 0.003341 | 18.33 | 18.24 | 18.33 | 17.56 | 17.78 | 17.46 | 2.48 |
SF3B1_MOUSE | 0.003346 | 12.56 | 13.20 | 12.99 | 10.58 | 9.66 | 11.43 | 2.48 |
SON_MOUSE | 0.003363 | 15.63 | 16.38 | 16.05 | 14.59 | 15.01 | 14.28 | 2.47 |
USO1_MOUSE | 0.003429 | 12.17 | 12.17 | 12.45 | 9.20 | 10.95 | 9.98 | 2.46 |
IMB1_MOUSE | 0.003496 | 17.29 | 17.51 | 16.97 | 16.38 | 16.41 | 16.06 | 2.46 |
S10A6_MOUSE | 0.003578 | 20.89 | 21.05 | 20.66 | 19.87 | 19.80 | 19.06 | 2.45 |
PPIA_MOUSE | 0.003862 | 20.57 | 20.18 | 20.41 | 19.71 | 19.67 | 19.62 | 2.41 |
RL14_MOUSE | 0.003872 | 16.09 | 15.94 | 15.68 | 14.82 | 14.68 | 15.23 | 2.41 |
RS8_MOUSE | 0.003989 | 15.56 | 15.41 | 15.45 | 13.37 | 14.24 | 14.45 | 2.40 |
PRDX1_MOUSE | 0.003992 | 18.09 | 18.49 | 18.10 | 17.08 | 17.53 | 16.93 | 2.40 |
MBB1A_MOUSE | 0.00401 | 13.93 | 13.88 | 13.57 | 12.52 | 12.26 | 11.16 | 2.40 |
EF1A1_MOUSE | 0.004196 | 18.52 | 18.47 | 18.60 | 17.73 | 18.02 | 17.90 | 2.38 |
SEPT2_MOUSE | 0.004277 | 15.38 | 14.98 | 15.32 | 14.00 | 13.59 | 14.44 | 2.37 |
ARF1_MOUSE | 0.004524 | 16.52 | 16.29 | 16.32 | 13.92 | 15.25 | 14.93 | 2.34 |
ADK_MOUSE | 0.004525 | 14.30 | 14.42 | 14.35 | 12.92 | 13.04 | 13.73 | 2.34 |
ATPK_MOUSE | 0.004911 | 16.16 | 15.57 | 14.97 | 13.98 | 14.08 | 14.28 | 2.31 |
VDAC3_MOUSE | 0.004948 | 15.00 | 15.20 | 14.34 | 13.66 | 13.76 | 13.72 | 2.31 |
RACK1_MOUSE | 0.005006 | 15.85 | 16.09 | 16.52 | 14.62 | 13.34 | 14.72 | 2.30 |
VATL_MOUSE | 0.005044 | 14.01 | 14.17 | 13.35 | 12.02 | 11.46 | 9.83 | 2.30 |
PRDX4_MOUSE | 0.005054 | 17.40 | 17.89 | 17.57 | 16.65 | 16.98 | 16.66 | 2.30 |
NUCL_MOUSE | 0.005137 | 19.18 | 18.99 | 18.89 | 18.37 | 18.33 | 18.48 | 2.29 |
SRP68_MOUSE | 0.00519 | 13.00 | 13.38 | 13.26 | 11.72 | 10.03 | 11.51 | 2.28 |
4F2_MOUSE | 0.005313 | 14.17 | 13.88 | 13.85 | 12.39 | 13.22 | 12.15 | 2.27 |
RIC8B_MOUSE | 0.005318 | 14.21 | 14.14 | 14.62 | 10.00 | 12.37 | 11.96 | 2.27 |
K1C14_MOUSE | 0.005548 | 14.01 | 14.36 | 12.72 | 15.38 | 16.00 | 15.93 | 2.26 |
UBA6_MOUSE | 0.005564 | 11.49 | 11.66 | 10.14 | 9.14 | 9.39 | 9.00 | 2.25 |
RL7A_MOUSE | 0.005709 | 15.36 | 15.63 | 14.99 | 14.33 | 14.52 | 14.49 | 2.24 |
SAP_MOUSE | 0.006308 | 18.39 | 18.62 | 18.60 | 19.01 | 19.41 | 19.32 | 2.20 |
MYL6_MOUSE | 0.006405 | 15.38 | 15.40 | 16.33 | 16.91 | 16.93 | 17.00 | 2.19 |
GTR1_MOUSE | 0.006448 | 14.20 | 13.70 | 14.27 | 10.09 | 12.49 | 11.59 | 2.19 |
CSN4_MOUSE | 0.006496 | 11.88 | 11.84 | 12.08 | 9.60 | 10.34 | 11.04 | 2.19 |
UGGG1_MOUSE | 0.006589 | 12.08 | 13.06 | 13.32 | 10.28 | 11.08 | 11.42 | 2.18 |
TCPD_MOUSE | 0.006742 | 14.59 | 14.85 | 14.80 | 14.23 | 13.67 | 13.94 | 2.17 |
IMA7_MOUSE | 0.007097 | 12.27 | 12.58 | 12.13 | 9.33 | 11.25 | 10.13 | 2.15 |
K1C13_MOUSE | 0.007257 | 17.30 | 16.66 | 16.85 | 17.75 | 17.99 | 17.70 | 2.14 |
VDAC2_MOUSE | 0.007331 | 15.12 | 15.16 | 15.24 | 14.16 | 13.27 | 14.32 | 2.13 |
GRP75_MOUSE | 0.007397 | 18.49 | 18.38 | 18.09 | 17.63 | 17.72 | 17.69 | 2.13 |
HEAT3_MOUSE | 0.007572 | 12.46 | 11.35 | 12.59 | 10.59 | 10.68 | 10.72 | 2.12 |
SMRC1_MOUSE | 0.007688 | 11.23 | 11.33 | 11.38 | 9.91 | 10.38 | 8.91 | 2.11 |
CDK1_MOUSE | 0.007805 | 9.17 | 10.81 | 10.28 | 7.99 | 8.33 | 8.49 | 2.11 |
AL7A1_MOUSE | 0.008283 | 14.00 | 13.86 | 13.60 | 10.32 | 12.37 | 12.01 | 2.08 |
PGAM1_MOUSE | 0.008302 | 20.10 | 19.97 | 20.04 | 19.21 | 19.51 | 19.57 | 2.08 |
ACON_MOUSE | 0.008378 | 14.44 | 14.12 | 13.91 | 11.95 | 10.17 | 12.61 | 2.08 |
UB2D2_MOUSE | 0.008403 | 13.84 | 14.98 | 14.95 | 12.17 | 12.82 | 13.37 | 2.08 |
UB2D3_MOUSE | 0.008403 | 13.84 | 14.98 | 14.95 | 12.17 | 12.82 | 13.37 | 2.08 |
K1C42_MOUSE | 0.008429 | 15.76 | 16.13 | 15.29 | 16.58 | 17.00 | 17.44 | 2.07 |
K22E_MOUSE | 0.008676 | 17.43 | 17.32 | 17.02 | 17.85 | 18.75 | 18.42 | 2.06 |
DPY30_MOUSE | 0.009099 | 14.38 | 14.41 | 14.24 | 13.73 | 13.58 | 13.94 | 2.04 |
CAND1_MOUSE | 0.009439 | 13.46 | 14.71 | 15.00 | 12.52 | 12.57 | 11.02 | 2.03 |
PYRG1_MOUSE | 0.00988 | 13.91 | 14.16 | 13.52 | 11.86 | 10.76 | 12.78 | 2.01 |
AT5G1_MOUSE | 0.010402 | 14.30 | 14.61 | 14.59 | 13.56 | 13.68 | 12.63 | 1.98 |
AT5G3_MOUSE | 0.010402 | 14.30 | 14.61 | 14.59 | 13.56 | 13.68 | 12.63 | 1.98 |
AT5G2_MOUSE | 0.010402 | 14.30 | 14.61 | 14.59 | 13.56 | 13.68 | 12.63 | 1.98 |
TLN1_MOUSE | 0.010823 | 12.88 | 13.67 | 13.19 | 11.53 | 12.54 | 11.78 | 1.97 |
HNRPL_MOUSE | 0.011041 | 14.09 | 14.70 | 14.00 | 12.95 | 13.54 | 12.50 | 1.96 |
CKAP4_MOUSE | 0.011183 | 15.39 | 15.64 | 15.70 | 14.98 | 14.96 | 15.14 | 1.95 |
RPN1_MOUSE | 0.011709 | 13.95 | 13.88 | 14.23 | 12.28 | 12.69 | 10.48 | 1.93 |
PFKAL_MOUSE | 0.01242 | 14.66 | 15.33 | 14.61 | 13.56 | 12.54 | 13.92 | 1.91 |
H13_MOUSE | 0.01257 | 17.64 | 17.48 | 17.53 | 18.10 | 18.20 | 17.90 | 1.90 |
CSN7A_MOUSE | 0.012775 | 13.73 | 13.81 | 13.95 | 13.46 | 13.15 | 12.94 | 1.89 |
LKHA4_MOUSE | 0.012846 | 12.57 | 12.89 | 11.55 | 9.83 | 11.25 | 9.36 | 1.89 |
RLA2_MOUSE | 0.013592 | 19.15 | 19.23 | 19.07 | 18.41 | 18.77 | 18.66 | 1.87 |
EIF3F_MOUSE | 0.01375 | 13.49 | 13.62 | 13.54 | 11.75 | 12.62 | 10.47 | 1.86 |
C1QBP_MOUSE | 0.01467 | 15.43 | 15.09 | 15.42 | 14.74 | 13.61 | 13.23 | 1.83 |
TAGL2_MOUSE | 0.0152 | 14.60 | 14.88 | 15.73 | 16.05 | 16.15 | 16.36 | 1.82 |
DESP_MOUSE | 0.015762 | 13.61 | 12.78 | 12.85 | 11.29 | 12.42 | 11.54 | 1.80 |
OTUB1_MOUSE | 0.019088 | 14.60 | 14.23 | 13.91 | 12.65 | 11.96 | 13.63 | 1.72 |
CALX_MOUSE | 0.020499 | 16.20 | 15.75 | 16.00 | 15.51 | 15.44 | 15.45 | 1.69 |
H12_MOUSE | 0.021046 | 16.68 | 16.42 | 16.57 | 16.88 | 17.14 | 17.05 | 1.68 |
ATPG_MOUSE | 0.02109 | 14.11 | 13.07 | 13.84 | 10.70 | 12.56 | 9.07 | 1.68 |
LAMP2_MOUSE | 0.021862 | 16.01 | 15.97 | 15.44 | 14.86 | 15.13 | 15.31 | 1.66 |
PSA5_MOUSE | 0.022314 | 15.01 | 15.16 | 15.13 | 14.48 | 14.81 | 14.20 | 1.65 |
TRY2_MOUSE | 0.022394 | 23.38 | 23.70 | 23.06 | 24.10 | 24.78 | 23.98 | 1.65 |
TCPA_MOUSE | 0.023869 | 14.28 | 14.09 | 14.44 | 8.73 | 12.79 | 11.64 | 1.62 |
RL12_MOUSE | 0.024021 | 15.04 | 14.26 | 14.99 | 14.18 | 13.84 | 13.44 | 1.62 |
BASP1_MOUSE | 0.024344 | 14.75 | 14.62 | 14.68 | 14.39 | 14.03 | 14.27 | 1.61 |
K1C19_MOUSE | 0.024816 | 20.16 | 20.03 | 20.09 | 20.34 | 20.63 | 20.70 | 1.61 |
EF1D_MOUSE | 0.026795 | 15.14 | 15.40 | 15.53 | 13.81 | 14.69 | 14.81 | 1.57 |
K2C4_MOUSE | 0.026904 | 16.58 | 16.50 | 16.10 | 17.07 | 20.58 | 20.30 | 1.57 |
PRDX5_MOUSE | 0.028629 | 15.67 | 14.57 | 15.15 | 14.44 | 14.17 | 13.68 | 1.54 |
THIO_MOUSE | 0.029175 | 17.68 | 17.83 | 17.73 | 17.41 | 17.43 | 17.31 | 1.53 |
YBOX2_MOUSE | 0.029181 | 16.07 | 15.87 | 16.09 | 15.42 | 15.41 | 15.77 | 1.53 |
YBOX3_MOUSE | 0.029181 | 16.07 | 15.87 | 16.09 | 15.42 | 15.41 | 15.77 | 1.53 |
TOM20_MOUSE | 0.030869 | 13.51 | 12.89 | 13.21 | 12.85 | 12.20 | 11.86 | 1.51 |
CH60_MOUSE | 0.031589 | 18.43 | 18.23 | 18.18 | 17.81 | 17.99 | 17.84 | 1.50 |
CD63_MOUSE | 0.03168 | 13.65 | 13.30 | 13.68 | 13.86 | 14.66 | 15.15 | 1.50 |
K2C8_MOUSE | 0.03168 | 17.18 | 16.87 | 17.34 | 16.74 | 16.58 | 16.62 | 1.50 |
TPIS_MOUSE | 0.031746 | 18.13 | 18.18 | 18.42 | 18.56 | 18.80 | 18.66 | 1.50 |
SODC_MOUSE | 0.033924 | 16.50 | 16.81 | 17.01 | 16.47 | 15.51 | 15.88 | 1.47 |
SYAC_MOUSE | 0.034719 | 14.61 | 14.49 | 14.41 | 14.20 | 12.04 | 12.45 | 1.46 |
SMU1_MOUSE | 0.036374 | 12.11 | 11.53 | 11.24 | 0.00 | 10.41 | 0.00 | 1.44 |
C1TM_MOUSE | 0.036422 | 12.82 | 13.00 | 13.37 | 11.36 | 8.63 | 11.91 | 1.44 |
ARF4_MOUSE | 0.036656 | 16.11 | 15.77 | 15.77 | 11.12 | 14.59 | 14.17 | 1.44 |
ANXA5_MOUSE | 0.036715 | 19.32 | 19.28 | 19.18 | 18.85 | 18.98 | 18.45 | 1.44 |
PARK7_MOUSE | 0.037258 | 13.64 | 14.02 | 13.39 | 12.77 | 13.09 | 11.55 | 1.43 |
P4HA1_MOUSE | 0.037299 | 14.18 | 14.14 | 14.57 | 13.57 | 14.02 | 13.65 | 1.43 |
THIKA_MOUSE | 0.037977 | 13.61 | 13.17 | 13.46 | 12.23 | 8.06 | 11.17 | 1.42 |
MTAP_MOUSE | 0.038542 | 15.04 | 14.85 | 14.92 | 14.72 | 14.39 | 14.51 | 1.41 |
THIC_MOUSE | 0.038635 | 10.87 | 11.76 | 11.13 | 10.35 | 10.69 | 10.57 | 1.41 |
LAP2B_MOUSE | 0.039043 | 14.57 | 14.75 | 14.52 | 14.24 | 14.14 | 14.35 | 1.41 |
NU155_MOUSE | 0.039897 | 12.47 | 11.90 | 10.75 | 10.88 | 10.26 | 9.88 | 1.40 |
TKT_MOUSE | 0.039985 | 13.72 | 14.07 | 13.84 | 12.88 | 10.86 | 13.00 | 1.40 |
CO1A1_MOUSE | 0.040121 | 13.56 | 13.79 | 12.40 | 11.31 | 12.66 | 11.63 | 1.40 |
CAPZB_MOUSE | 0.040224 | 14.17 | 14.21 | 13.87 | 10.09 | 13.29 | 12.32 | 1.40 |
VDAC1_MOUSE | 0.042968 | 17.38 | 16.30 | 17.24 | 16.26 | 16.19 | 15.97 | 1.37 |
NP1L1_MOUSE | 0.043459 | 16.89 | 17.08 | 17.00 | 16.56 | 16.77 | 16.57 | 1.36 |
TSSK5_MOUSE | 0.044033 | 16.69 | 16.56 | 16.64 | 0.00 | 11.28 | 12.35 | 1.36 |
PEBP1_MOUSE | 0.044407 | 16.86 | 16.87 | 17.32 | 16.39 | 16.63 | 16.60 | 1.35 |
H4_MOUSE | 0.044792 | 18.83 | 19.42 | 18.62 | 17.86 | 18.65 | 17.62 | 1.35 |
NPM_MOUSE | 0.049164 | 16.09 | 15.74 | 16.14 | 16.16 | 16.87 | 17.01 | 1.31 |
EF1B_MOUSE | 0.04968 | 16.12 | 16.36 | 16.28 | 15.74 | 15.48 | 16.08 | 1.30 |
PSD13_MOUSE | 0.051249 | 11.93 | 11.08 | 11.28 | 10.38 | 11.13 | 10.10 | 1.29 |
PAIRB_MOUSE | 0.05299 | 15.41 | 15.12 | 15.11 | 15.45 | 15.65 | 15.68 | 1.28 |
PLEC_MOUSE | 0.05689 | 13.93 | 14.45 | 14.22 | 13.50 | 12.90 | 10.57 | 1.24 |
H2B1K_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1C_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1H_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1F_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B3B_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B3A_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1P_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B2B_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B2E_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1B_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
H2B1M_MOUSE | 0.058515 | 12.26 | 12.50 | 13.57 | 10.16 | 12.41 | 11.01 | 1.23 |
HNRPK_MOUSE | 0.060011 | 18.52 | 18.54 | 18.47 | 17.59 | 18.44 | 17.70 | 1.22 |
KLC4_MOUSE | 0.060749 | 12.56 | 0.00 | 14.57 | 17.84 | 17.96 | 18.79 | 1.22 |
1433Z_MOUSE | 0.061261 | 18.97 | 19.31 | 19.48 | 18.83 | 18.90 | 18.83 | 1.21 |
GSHR_MOUSE | 0.067255 | 11.26 | 11.97 | 11.15 | 11.44 | 8.39 | 8.57 | 1.17 |
RS23_MOUSE | 0.067883 | 14.28 | 13.20 | 14.33 | 13.23 | 12.76 | 13.34 | 1.17 |
IF4B_MOUSE | 0.069049 | 14.02 | 14.03 | 13.57 | 13.24 | 13.33 | 11.59 | 1.16 |
CALM3_MOUSE | 0.069229 | 18.81 | 18.84 | 18.56 | 18.90 | 19.25 | 19.72 | 1.16 |
CALM2_MOUSE | 0.069229 | 18.81 | 18.84 | 18.56 | 18.90 | 19.25 | 19.72 | 1.16 |
CALM1_MOUSE | 0.069229 | 18.81 | 18.84 | 18.56 | 18.90 | 19.25 | 19.72 | 1.16 |
ATP5J_MOUSE | 0.072899 | 13.97 | 14.29 | 14.26 | 13.62 | 13.68 | 14.03 | 1.14 |
COPG1_MOUSE | 0.074631 | 14.63 | 14.90 | 14.06 | 12.58 | 14.17 | 13.74 | 1.13 |
CPNE1_MOUSE | 0.07629 | 9.39 | 10.50 | 11.33 | 9.91 | 8.84 | 8.39 | 1.12 |
RAB1B_MOUSE | 0.077103 | 15.28 | 14.29 | 14.56 | 13.56 | 14.43 | 13.86 | 1.11 |
RAB1A_MOUSE | 0.077103 | 15.28 | 14.29 | 14.56 | 13.56 | 14.43 | 13.86 | 1.11 |
PCNA_MOUSE | 0.077431 | 14.30 | 12.74 | 13.33 | 12.28 | 11.76 | 13.01 | 1.11 |
RBBP7_MOUSE | 0.077454 | 13.35 | 15.62 | 15.59 | 15.96 | 16.83 | 16.23 | 1.11 |
RBBP4_MOUSE | 0.077454 | 13.35 | 15.62 | 15.59 | 15.96 | 16.83 | 16.23 | 1.11 |
H2AV_MOUSE | 0.07878 | 18.16 | 18.27 | 18.00 | 17.72 | 17.79 | 17.97 | 1.10 |
H2AZ_MOUSE | 0.07878 | 18.16 | 18.27 | 18.00 | 17.72 | 17.79 | 17.97 | 1.10 |
AN32A_MOUSE | 0.09057 | 19.92 | 19.71 | 19.91 | 20.11 | 20.81 | 20.08 | 1.04 |
K2C5_MOUSE | 0.090801 | 18.63 | 18.91 | 18.73 | 17.67 | 18.00 | 18.75 | 1.04 |
TEBP_MOUSE | 0.092832 | 14.31 | 14.27 | 14.67 | 14.25 | 13.87 | 14.03 | 1.03 |
AN32B_MOUSE | 0.094555 | 19.89 | 19.70 | 19.87 | 20.08 | 20.79 | 20.05 | 1.02 |
G3P_MOUSE | 0.097292 | 19.35 | 19.40 | 19.66 | 17.89 | 19.16 | 19.09 | 1.01 |
LRC59_MOUSE | 0.097584 | 14.27 | 15.08 | 14.15 | 14.70 | 15.56 | 15.31 | 1.01 |
XPO1_MOUSE | 0.099533 | 13.56 | 13.24 | 13.89 | 13.07 | 13.38 | 12.77 | 1.00 |
UBE2N_MOUSE | 0.100923 | 15.22 | 14.93 | 14.57 | 14.29 | 13.85 | 14.79 | 1.00 |
RS3A_MOUSE | 0.103532 | 16.06 | 15.61 | 15.98 | 11.72 | 15.25 | 14.96 | 0.98 |
CNBP_MOUSE | 0.103689 | 12.35 | 14.37 | 14.12 | 15.04 | 14.54 | 14.59 | 0.98 |
PHB2_MOUSE | 0.104427 | 14.67 | 14.13 | 13.97 | 13.95 | 13.60 | 12.01 | 0.98 |
SC61B_MOUSE | 0.106335 | 13.45 | 13.48 | 12.63 | 13.93 | 14.12 | 13.38 | 0.97 |
P5CS_MOUSE | 0.108547 | 9.54 | 10.84 | 10.65 | 9.90 | 9.66 | 8.91 | 0.96 |
LBH_MOUSE | 0.116272 | 14.11 | 13.63 | 12.91 | 13.96 | 14.14 | 14.49 | 0.93 |
ML12B_MOUSE | 0.118359 | 17.10 | 16.86 | 16.90 | 17.04 | 17.58 | 17.28 | 0.93 |
ENOA_MOUSE | 0.119211 | 19.91 | 19.66 | 19.75 | 19.97 | 20.15 | 19.97 | 0.92 |
RTRAF_MOUSE | 0.120351 | 9.09 | 10.08 | 9.42 | 9.90 | 10.19 | 10.06 | 0.92 |
PLBL2_MOUSE | 0.125355 | 10.46 | 9.89 | 10.73 | 9.65 | 0.00 | 7.75 | 0.90 |
K2C6B_MOUSE | 0.134139 | 18.83 | 19.04 | 18.86 | 17.95 | 18.42 | 18.93 | 0.87 |
K2C6A_MOUSE | 0.134139 | 18.83 | 19.04 | 18.86 | 17.95 | 18.42 | 18.93 | 0.87 |
K2C75_MOUSE | 0.134139 | 18.83 | 19.04 | 18.86 | 17.95 | 18.42 | 18.93 | 0.87 |
RINI_MOUSE | 0.135641 | 10.54 | 13.30 | 12.66 | 8.46 | 11.63 | 10.75 | 0.87 |
TOM70_MOUSE | 0.136482 | 8.39 | 10.68 | 11.45 | 12.25 | 12.00 | 10.84 | 0.86 |
NDKA_MOUSE | 0.137404 | 15.14 | 15.82 | 16.17 | 16.20 | 16.09 | 16.32 | 0.86 |
K1C12_MOUSE | 0.138179 | 14.33 | 12.40 | 13.09 | 11.04 | 9.90 | 13.51 | 0.86 |
GRM7_MOUSE | 0.144146 | 11.24 | 12.54 | 12.50 | 9.36 | 11.47 | 0.00 | 0.84 |
RL40_MOUSE | 0.147393 | 19.31 | 18.88 | 18.98 | 18.04 | 18.14 | 19.20 | 0.83 |
RS27A_MOUSE | 0.147393 | 19.31 | 18.88 | 18.98 | 18.04 | 18.14 | 19.20 | 0.83 |
UBC_MOUSE | 0.147393 | 19.31 | 18.88 | 18.98 | 18.04 | 18.14 | 19.20 | 0.83 |
UBB_MOUSE | 0.147393 | 19.31 | 18.88 | 18.98 | 18.04 | 18.14 | 19.20 | 0.83 |
M21_MPV15 | 0.148508 | 8.24 | 15.22 | 15.12 | 16.19 | 16.17 | 16.15 | 0.83 |
NAA15_MOUSE | 0.150828 | 13.48 | 13.36 | 12.60 | 13.06 | 12.46 | 11.03 | 0.82 |
RS14_MOUSE | 0.151861 | 14.26 | 15.89 | 16.28 | 14.67 | 14.50 | 14.57 | 0.82 |
PDIA3_MOUSE | 0.153504 | 15.84 | 16.03 | 15.35 | 15.16 | 15.70 | 14.97 | 0.81 |
EF1G_MOUSE | 0.156411 | 13.27 | 13.92 | 13.27 | 13.39 | 13.03 | 12.04 | 0.81 |
LEG1_MOUSE | 0.1623 | 18.70 | 18.71 | 18.85 | 18.59 | 19.60 | 19.56 | 0.79 |
PGRC1_MOUSE | 0.163353 | 14.32 | 14.37 | 13.93 | 14.08 | 13.96 | 13.18 | 0.79 |
ECI1_MOUSE | 0.163424 | 11.09 | 12.41 | 11.78 | 11.44 | 10.80 | 11.21 | 0.79 |
YBOX1_MOUSE | 0.164124 | 16.68 | 15.95 | 16.70 | 15.46 | 16.04 | 16.29 | 0.78 |
NACA_MOUSE | 0.164437 | 14.53 | 14.47 | 14.50 | 14.01 | 13.06 | 14.55 | 0.78 |
NACAM_MOUSE | 0.164437 | 14.53 | 14.47 | 14.50 | 14.01 | 13.06 | 14.55 | 0.78 |
CNPY2_MOUSE | 0.17626 | 12.46 | 12.99 | 10.04 | 13.61 | 13.63 | 12.29 | 0.75 |
RS25_MOUSE | 0.183649 | 14.17 | 15.71 | 15.46 | 15.74 | 16.79 | 15.35 | 0.74 |
ERD21_MOUSE | 0.186208 | 13.46 | 13.59 | 12.78 | 14.44 | 13.81 | 13.28 | 0.73 |
PSMD7_MOUSE | 0.187718 | 12.96 | 13.17 | 10.64 | 11.64 | 9.38 | 11.52 | 0.73 |
1433T_MOUSE | 0.192931 | 14.35 | 17.16 | 17.25 | 17.07 | 17.93 | 17.52 | 0.71 |
AIMP2_MOUSE | 0.19423 | 10.62 | 11.43 | 10.63 | 10.92 | 9.42 | 10.34 | 0.71 |
1433F_MOUSE | 0.201946 | 10.88 | 16.87 | 16.97 | 16.94 | 17.85 | 17.47 | 0.69 |
SCOT1_MOUSE | 0.206602 | 13.33 | 15.39 | 15.53 | 13.71 | 12.49 | 14.59 | 0.68 |
1433B_MOUSE | 0.2371 | 15.42 | 17.34 | 17.39 | 17.11 | 17.88 | 17.52 | 0.63 |
NPHP3_MOUSE | 0.243422 | 15.80 | 15.77 | 14.74 | 13.76 | 15.10 | 15.37 | 0.61 |
RL30_MOUSE | 0.247419 | 17.16 | 15.05 | 17.18 | 15.81 | 15.95 | 15.10 | 0.61 |
ELOV5_MOUSE | 0.258405 | 13.97 | 13.78 | 13.99 | 13.88 | 13.83 | 12.76 | 0.59 |
NPC2_MOUSE | 0.259318 | 11.08 | 11.64 | 12.19 | 11.76 | 10.87 | 10.79 | 0.59 |
DNPEP_MOUSE | 0.264156 | 13.89 | 11.40 | 13.97 | 13.04 | 9.50 | 12.33 | 0.58 |
ARSA_MOUSE | 0.264454 | 13.47 | 10.82 | 11.47 | 10.86 | 11.57 | 10.60 | 0.58 |
TPM3_MOUSE | 0.266344 | 17.81 | 17.98 | 17.64 | 18.06 | 18.04 | 17.89 | 0.57 |
RS5_MOUSE | 0.266611 | 17.31 | 17.41 | 17.23 | 17.32 | 17.65 | 17.53 | 0.57 |
RS13_MOUSE | 0.285418 | 13.47 | 14.36 | 13.52 | 12.41 | 13.83 | 13.49 | 0.54 |
PUR9_MOUSE | 0.285772 | 10.00 | 8.60 | 10.64 | 9.62 | 8.78 | 8.79 | 0.54 |
PTK6_MOUSE | 0.28915 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.70 | 0.54 |
K2C79_MOUSE | 0.289352 | 18.86 | 19.12 | 18.84 | 18.83 | 19.52 | 19.25 | 0.54 |
K2C7_MOUSE | 0.292854 | 15.60 | 15.21 | 15.45 | 15.42 | 15.55 | 16.08 | 0.53 |
GFAP_MOUSE | 0.292854 | 15.60 | 15.21 | 15.45 | 15.42 | 15.55 | 16.08 | 0.53 |
KRT85_MOUSE | 0.292854 | 15.60 | 15.21 | 15.45 | 15.42 | 15.55 | 16.08 | 0.53 |
VATE1_MOUSE | 0.298284 | 12.38 | 12.47 | 12.01 | 12.23 | 12.30 | 10.48 | 0.53 |
UNC79_MOUSE | 0.301243 | 9.70 | 11.27 | 0.00 | 10.56 | 10.17 | 10.54 | 0.52 |
TPM1_MOUSE | 0.310726 | 17.63 | 17.77 | 17.32 | 17.80 | 17.70 | 17.76 | 0.51 |
ROAA_MOUSE | 0.312399 | 17.53 | 17.26 | 17.46 | 17.13 | 17.28 | 17.35 | 0.51 |
TCPQ_MOUSE | 0.328145 | 14.84 | 13.00 | 14.61 | 12.67 | 13.87 | 13.94 | 0.48 |
IPO4_MOUSE | 0.330746 | 10.94 | 12.57 | 12.78 | 11.74 | 11.10 | 11.72 | 0.48 |
RB11A_MOUSE | 0.332879 | 12.52 | 12.83 | 10.92 | 11.77 | 11.88 | 10.66 | 0.48 |
FUS_MOUSE | 0.334276 | 14.99 | 14.25 | 14.38 | 14.36 | 14.39 | 14.12 | 0.48 |
RL9_MOUSE | 0.335137 | 11.52 | 14.10 | 14.36 | 11.45 | 12.84 | 12.90 | 0.47 |
PSME2_MOUSE | 0.345432 | 10.59 | 12.14 | 12.92 | 12.12 | 12.94 | 12.54 | 0.46 |
RL22_MOUSE | 0.356258 | 14.62 | 15.45 | 14.44 | 14.52 | 14.64 | 14.47 | 0.45 |
H2AX_MOUSE | 0.363435 | 19.34 | 19.36 | 18.97 | 19.20 | 19.02 | 18.95 | 0.44 |
PGK1_MOUSE | 0.365098 | 17.57 | 17.47 | 17.76 | 17.39 | 17.38 | 17.60 | 0.44 |
ACTB_MOUSE | 0.372193 | 16.23 | 17.58 | 17.39 | 16.60 | 17.10 | 16.23 | 0.43 |
RS15_MOUSE | 0.373532 | 8.56 | 11.70 | 9.45 | 11.67 | 9.21 | 12.03 | 0.43 |
H2A2B_MOUSE | 0.375984 | 19.31 | 19.32 | 18.93 | 19.14 | 18.99 | 18.94 | 0.42 |
TCTP_MOUSE | 0.389556 | 15.70 | 16.11 | 16.01 | 16.15 | 15.85 | 16.41 | 0.41 |
K2C73_MOUSE | 0.394735 | 17.48 | 17.28 | 17.24 | 17.18 | 16.86 | 17.43 | 0.40 |
1433G_MOUSE | 0.397852 | 16.37 | 17.70 | 17.82 | 17.36 | 18.05 | 17.71 | 0.40 |
NDKB_MOUSE | 0.400574 | 15.12 | 15.57 | 15.59 | 15.81 | 15.35 | 15.69 | 0.40 |
RLA1_MOUSE | 0.409863 | 18.51 | 18.47 | 18.84 | 18.63 | 18.76 | 18.85 | 0.39 |
ABCE1_MOUSE | 0.411465 | 14.21 | 12.17 | 14.39 | 13.79 | 11.70 | 13.11 | 0.39 |
PUR4_MOUSE | 0.415174 | 13.27 | 13.77 | 12.35 | 13.18 | 13.17 | 11.32 | 0.38 |
H2AJ_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1K_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1H_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1F_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A3_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1P_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1O_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1N_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1I_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1G_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1E_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1D_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1C_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A1B_MOUSE | 0.419493 | 19.30 | 19.32 | 18.91 | 19.17 | 18.99 | 18.92 | 0.38 |
H2A2A_MOUSE | 0.436243 | 19.27 | 19.28 | 18.86 | 19.11 | 18.96 | 18.91 | 0.36 |
H2A2C_MOUSE | 0.436243 | 19.27 | 19.28 | 18.86 | 19.11 | 18.96 | 18.91 | 0.36 |
RS17_MOUSE | 0.439512 | 13.88 | 10.54 | 13.59 | 13.79 | 12.66 | 14.01 | 0.36 |
LYAG_MOUSE | 0.450325 | 12.54 | 9.97 | 11.66 | 10.70 | 10.94 | 10.93 | 0.35 |
THOC4_MOUSE | 0.462349 | 14.38 | 14.69 | 14.65 | 14.27 | 14.65 | 14.39 | 0.34 |
ALRF2_MOUSE | 0.462349 | 14.38 | 14.69 | 14.65 | 14.27 | 14.65 | 14.39 | 0.34 |
NDUA4_MOUSE | 0.471139 | 13.69 | 12.04 | 13.71 | 12.39 | 12.33 | 13.40 | 0.33 |
AT5F1_MOUSE | 0.482549 | 16.29 | 12.89 | 14.77 | 12.77 | 14.33 | 14.64 | 0.32 |
RM12_MOUSE | 0.506745 | 13.70 | 13.65 | 12.79 | 13.52 | 13.33 | 12.46 | 0.30 |
RCN2_MOUSE | 0.518016 | 14.14 | 13.87 | 13.66 | 13.93 | 13.85 | 14.32 | 0.29 |
RS10_MOUSE | 0.52846 | 11.58 | 14.25 | 14.08 | 12.52 | 13.43 | 12.35 | 0.28 |
RL31_MOUSE | 0.540627 | 16.99 | 16.90 | 15.24 | 15.88 | 16.37 | 15.86 | 0.27 |
RS18_MOUSE | 0.556426 | 12.92 | 12.59 | 12.58 | 12.37 | 12.42 | 12.91 | 0.25 |
TCEA1_MOUSE | 0.565193 | 12.59 | 14.22 | 13.07 | 13.90 | 10.80 | 13.47 | 0.25 |
TMED9_MOUSE | 0.58254 | 12.07 | 12.94 | 9.11 | 13.17 | 11.80 | 11.11 | 0.23 |
GSTP2_MOUSE | 0.589048 | 16.49 | 14.57 | 15.66 | 15.38 | 15.37 | 15.13 | 0.23 |
GSTP1_MOUSE | 0.589048 | 16.49 | 14.57 | 15.66 | 15.38 | 15.37 | 15.13 | 0.23 |
SKP1_MOUSE | 0.610602 | 12.96 | 15.48 | 15.74 | 15.01 | 15.06 | 15.35 | 0.21 |
QCR2_MOUSE | 0.618647 | 10.32 | 9.89 | 11.16 | 11.05 | 9.97 | 9.53 | 0.21 |
AQP1_MOUSE | 0.642568 | 8.72 | 9.75 | 11.31 | 9.64 | 11.31 | 9.98 | 0.19 |
MTPN_MOUSE | 0.674227 | 13.79 | 14.86 | 14.62 | 14.51 | 14.60 | 13.64 | 0.17 |
ARL1_MOUSE | 0.677382 | 14.41 | 13.58 | 14.00 | 14.95 | 14.22 | 13.41 | 0.17 |
SCRB2_MOUSE | 0.678152 | 12.27 | 11.87 | 11.01 | 11.23 | 12.12 | 11.24 | 0.17 |
K2C1B_MOUSE | 0.689647 | 18.32 | 18.49 | 18.36 | 18.23 | 18.37 | 18.80 | 0.16 |
PTMA_MOUSE | 0.696432 | 21.09 | 21.06 | 21.09 | 21.06 | 21.37 | 20.99 | 0.16 |
1433E_MOUSE | 0.697313 | 18.88 | 19.57 | 19.80 | 19.17 | 19.76 | 18.90 | 0.16 |
TPM4_MOUSE | 0.7118 | 19.25 | 19.19 | 18.96 | 18.93 | 19.47 | 19.23 | 0.15 |
S10AA_MOUSE | 0.715815 | 12.43 | 14.11 | 14.26 | 13.96 | 13.71 | 13.74 | 0.15 |
MARCS_MOUSE | 0.726697 | 14.39 | 14.24 | 13.95 | 14.54 | 14.64 | 13.72 | 0.14 |
CAPR1_MOUSE | 0.731991 | 12.49 | 13.16 | 13.04 | 12.61 | 12.96 | 13.42 | 0.14 |
SET_MOUSE | 0.745103 | 17.88 | 18.09 | 18.00 | 17.96 | 18.02 | 17.86 | 0.13 |
PLP2_MOUSE | 0.748147 | 11.74 | 13.38 | 12.77 | 13.13 | 12.22 | 12.02 | 0.13 |
ATPD_MOUSE | 0.758636 | 11.61 | 12.28 | 12.48 | 11.64 | 13.01 | 11.20 | 0.12 |
PUSL1_MOUSE | 0.767776 | 10.10 | 12.69 | 12.69 | 9.81 | 11.75 | 12.92 | 0.11 |
ACTY_MOUSE | 0.782008 | 11.23 | 13.96 | 14.26 | 13.44 | 13.43 | 13.30 | 0.11 |
ACTZ_MOUSE | 0.782008 | 11.23 | 13.96 | 14.26 | 13.44 | 13.43 | 13.30 | 0.11 |
DBF4A_MOUSE | 0.788214 | 12.57 | 0.00 | 0.00 | 0.00 | 0.00 | 17.81 | 0.10 |
GPM6A_MOUSE | 0.809664 | 18.65 | 18.79 | 18.22 | 19.09 | 18.01 | 18.80 | 0.09 |
PSME1_MOUSE | 0.842895 | 12.30 | 13.00 | 13.15 | 12.88 | 13.04 | 12.70 | 0.07 |
COX41_MOUSE | 0.930115 | 11.07 | 14.37 | 14.74 | 12.28 | 13.97 | 13.62 | 0.03 |
PP14B_MOUSE | 0.932589 | 12.48 | 12.62 | 12.40 | 12.41 | 12.79 | 12.25 | 0.03 |
CO6A1_MOUSE | 0.945765 | 9.84 | 11.39 | 10.75 | 12.41 | 9.66 | 9.73 | 0.02 |
CO1A2_MOUSE | 0.94961 | 11.48 | 14.35 | 13.89 | 12.85 | 13.72 | 13.31 | 0.02 |
HARS1_MOUSE | 0.960346 | 9.84 | 10.24 | 11.74 | 11.12 | 10.46 | 10.32 | 0.02 |
CALR_MOUSE | 0.967791 | 16.10 | 16.32 | 16.31 | 16.07 | 15.89 | 16.80 | 0.01 |
BAP31_MOUSE | 0.973337 | 10.98 | 13.81 | 13.19 | 12.35 | 13.30 | 12.25 | 0.01 |
EI3JB_MOUSE | 0.97778 | 12.28 | 12.65 | 11.10 | 10.89 | 12.88 | 12.31 | 0.01 |
EI3JA_MOUSE | 0.97778 | 12.28 | 12.65 | 11.10 | 10.89 | 12.88 | 12.31 | 0.01 |
MIF_MOUSE | 0.98048 | 18.20 | 18.05 | 18.36 | 17.61 | 19.16 | 17.87 | 0.01 |
Author Contributions
Conceptualization, S.K. and Y.Y.; methodology, T.M., C.C. and P.S.; software, S.K. and Y.Y.; validation, K.C., Y.Y. and K.C.; formal analysis, S.K. and Y.Y.; investigation, P.P.; resources, W.V. and K.C.; data curation, C.C. and K.C.; writing—original draft preparation, S.K.; writing—review and editing, S.K. and Y.Y.; visualization, T.M.; supervision, P.S. and C.C.; project administration, K.C.; funding acquisition, K.C. All authors have read and agreed to the published version of the manuscript.
Funding
This study was supported by the National Research Council of Thailand (NRCT) under the Royal Golden Jubilee Ph.D. Program (Grant No. NRCT5-RGJ63002-042) and Kasetsart University Research and Development Institute, KURDI (FF (KU)25.64).
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Udenigwe C.C., Aluko R.E. Food protein-derived bioactive peptides: Production, processing, and potential health benefits. J. Food Sci. 2012;77:R11–R24. doi: 10.1111/j.1750-3841.2011.02455.x. [DOI] [PubMed] [Google Scholar]
- 2.Aoyama T., Fukui K., Takamatsu K., Hashimoto Y., Yamamoto T. Soy protein isolate and its hydrolysate reduce body fat of dietary obese rats and genetically obese mice (yellow KK) Nutrition. 2000;16:349–354. doi: 10.1016/S0899-9007(00)00230-6. [DOI] [PubMed] [Google Scholar]
- 3.Bruno B.J., Miller G.D., Lim C.S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 2013;4:1443–1467. doi: 10.4155/tde.13.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jo Feeney M., Miller A.M., Roupas P. Mushrooms-biologically distinct and nutritionally unique: Exploring a “third food kingdom”. Nutr. Today. 2014;49:301–307. doi: 10.1097/NT.0000000000000063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Mendoza G., Suarez-Medellin J., Espinoza C., Ramos-Ligonio A., Fernandez J.J., Norte M., Trigos A. Isolation and characterization of bioactive metabolites from fruiting bodies and mycelial culture of ganoderma oerstedii (higher basidiomycetes) from Mexico. Int. J. Med. Mushrooms. 2015;17:501–509. doi: 10.1615/IntJMedMushrooms.v17.i6.10. [DOI] [PubMed] [Google Scholar]
- 6.Cao Q.Z., Lin Z.B. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci. 2006;78:1457–1463. doi: 10.1016/j.lfs.2005.07.017. [DOI] [PubMed] [Google Scholar]
- 7.Sanodiya B.S., Thakur G.S., Baghel R.K., Prasad G.B., Bisen P.S. Ganoderma lucidum: A potent pharmacological macrofungus. Curr. Pharm. Biotechnol. 2009;10:717–742. doi: 10.2174/138920109789978757. [DOI] [PubMed] [Google Scholar]
- 8.Yoon H.M., Jang K.J., Han M.S., Jeong J.W., Kim G.Y., Lee J.H., Choi Y.H. Ganoderma lucidum ethanol extract inhibits the inflammatory response by suppressing the NF-kappaB and toll-like receptor pathways in lipopolysaccharide-stimulated BV2 microglial cells. Exp. Ther. Med. 2013;5:957–963. doi: 10.3892/etm.2013.895. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Krobthong S., Choowongkomon K., Suphakun P., Kuaprasert B., Samutrtai P., Yingchutrakul Y. The anti-oxidative effect of Lingzhi protein hydrolysates on lipopolysaccharide-stimulated A549 cells. Food Biosci. 2021;41:101093. doi: 10.1016/j.fbio.2021.101093. [DOI] [Google Scholar]
- 10.Hayes M. Food proteins and bioactive peptides: New and novel sources, characterisation strategies and applications. Foods. 2018;7:38. doi: 10.3390/foods7030038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Udenigwe C.C., Mohan A., Wu S. Peptide aggregation during plastein reaction enhanced bile acid-binding capacity of enzymatic chicken meat hydrolysates. J. Food Biochem. 2015;39:344–348. doi: 10.1111/jfbc.12139. [DOI] [Google Scholar]
- 12.Segura-Campos M., Chel-Guerrero L., Betancur-Ancona D., Hernandez-Escalante V.M. Bioavailability of bioactive peptides. Food Rev. Int. 2011;27:213–226. doi: 10.1080/87559129.2011.563395. [DOI] [Google Scholar]
- 13.McClements D.J. Nanoparticle and Microparticle-based Delivery Systems: Encapsulation, Protection and Release of Active Compounds. Taylor & Francis; Oxfordshire, UK: 2014. [Google Scholar]
- 14.Allen T.M., Cullis P.R. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug. Deliv. Rev. 2013;65:36–48. doi: 10.1016/j.addr.2012.09.037. [DOI] [PubMed] [Google Scholar]
- 15.Moeller E.H., Holst B., Nielsen L.H., Pedersen P.S., Ostergaard J. Stability, liposome interaction, and in vivo pharmacology of ghrelin in liposomal suspensions. Int. J. Pharm. 2010;390:13–18. doi: 10.1016/j.ijpharm.2009.05.067. [DOI] [PubMed] [Google Scholar]
- 16.Pisal D.S., Kosloski M.P., Balu-Iyer S.V. Delivery of therapeutic proteins. J. Pharm. Sci. 2010;99:2557–2575. doi: 10.1002/jps.22054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009;30:592–599. doi: 10.1016/j.tips.2009.08.004. [DOI] [PubMed] [Google Scholar]
- 18.Sereewatthanawut I., Prapintip S., Watchiraruji K., Goto M., Sasaki M., Shotipruk A. Extraction of protein and amino acids from deoiled rice bran by subcritical water hydrolysis. Bioresour. Technol. 2008;99:555–561. doi: 10.1016/j.biortech.2006.12.030. [DOI] [PubMed] [Google Scholar]
- 19.Nielsen P.M., Petersen D., Dambmann C. Improved method for determining food protein degree of hydrolysis. J. Food Sci. 2001;66:642–646. doi: 10.1111/j.1365-2621.2001.tb04614.x. [DOI] [Google Scholar]
- 20.Riss T.L., Moravec R.A., Niles A.L., Duellman S., Benink H.A., Worzella T.J., Minor L. Cell viability assays. In: Sittampalam G.S., Grossman A., Brimacombe K., Arkin M., Auld D., Austin C.P., Baell J., Bejcek B., Caaveiro J.M.M., Chung T.D.Y., et al., editors. Assay Guidance Manual. Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences; Bethesda, MD, USA: 2004. [Google Scholar]
- 21.Shilov I.V., Seymour S.L., Patel A.A., Loboda A., Tang W.H., Keating S.P., Hunter C.L., Nuwaysir L.M., Schaeffer D.A. The paragon algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteom. 2007;6:1638–1655. doi: 10.1074/mcp.T600050-MCP200. [DOI] [PubMed] [Google Scholar]
- 22.Willforss J., Chawade A., Levander F. NormalyzerDE: Online tool for improved normalization of omics expression data and high-sensitivity differential expression analysis. J. Proteome. Res. 2019;18:732–740. doi: 10.1021/acs.jproteome.8b00523. [DOI] [PubMed] [Google Scholar]
- 23.DeFelice S.L. The nutraceutical revolution: Its impact on food industry R&D. Trends Food Sci. Technol. 1995;6:59–61. doi: 10.1016/S0924-2244(00)88944-X. [DOI] [Google Scholar]
- 24.Rebeca B.D., Peña-Vera M.T., Díaz-Castañeda M. Production of fish protein hydrolysates with bacterial proteases; yield and nutritional value. J. Food Sci. 1991;56:309–314. doi: 10.1111/j.1365-2621.1991.tb05268.x. [DOI] [Google Scholar]
- 25.Ruderman G., Grigera J.R. Effect of Triton X-100 on the physical properties of liposomes. Biochim. Biophys. Acta. 1986;863:277–281. doi: 10.1016/0005-2736(86)90267-1. [DOI] [PubMed] [Google Scholar]
- 26.Gupta K., Jang H., Harlen K., Puri A., Nussinov R., Schneider J.P., Blumenthal R. Mechanism of membrane permeation induced by synthetic beta-hairpin peptides. Biophys. J. 2013;105:2093–2103. doi: 10.1016/j.bpj.2013.09.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Smith M.C., Crist R.M., Clogston J.D., McNeil S.E. Zeta potential: A case study of cationic, anionic, and neutral liposomes. Anal. Bioanal. Chem. 2017;409:5779–5787. doi: 10.1007/s00216-017-0527-z. [DOI] [PubMed] [Google Scholar]
- 28.Andar A.U., Hood R.R., Vreeland W.N., Devoe D.L., Swaan P.W. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm. Res. 2014;31:401–413. doi: 10.1007/s11095-013-1171-8. [DOI] [PubMed] [Google Scholar]
- 29.Sheng Y., Chang L., Kuang T., Hu J. PEG/heparin-decorated lipid–polymer hybrid nanoparticles for long-circulating drug delivery. RSC Adv. 2016;6:23279–23287. doi: 10.1039/C5RA26215A. [DOI] [Google Scholar]
- 30.Taira M.C., Chiaramoni N.S., Pecuch K.M., Alonso-Romanowski S. Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv. 2004;11:123–128. doi: 10.1080/10717540490280769. [DOI] [PubMed] [Google Scholar]
- 31.Kim J., Jang D.S., Kim H., Kim J.S. Anti-lipase and lipolytic activities of ursolic acid isolated from the roots of Actinidia arguta. Arch. Pharmacal Res. 2009;32:983–987. doi: 10.1007/s12272-009-1702-3. [DOI] [PubMed] [Google Scholar]
- 32.Fernandez-Galilea M., Perez-Matute P., Prieto-Hontoria P.L., Martinez J.A., Moreno-Aliaga M.J. Effects of lipoic acid on lipolysis in 3T3-L1 adipocytes. J. Lipid Res. 2012;53:2296–2306. doi: 10.1194/jlr.M027086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Valikangas T., Suomi T., Elo L.L. A systematic evaluation of normalization methods in quantitative label-free proteomics. Brief Bioinform. 2018;19:1–11. doi: 10.1093/bib/bbw095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Wang Y., Botolin D., Xu J., Christian B., Mitchell E., Jayaprakasam B., Nair M.G., Peters J.M., Busik J.V., Olson L.K., et al. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 2006;47:2028–2041. doi: 10.1194/jlr.M600177-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Not applicable.